Postdoctoral PDDM912 ⭐ 4 Credits Semester 2

Semisolid Release Testing and Physical Characterization Mapped to the Real Lab

Builds an API-agnostic analytical control strategy for nonsterile creams, ointments, lotions and gels, using USP <3> (Topical and Transdermal Drug Products—Product Quality Tests) as the backbone. The course keeps five test purposes strictly separate: development characterization, incoming component testing, in-process controls (IPC), release, and stability/comparability. Each test is assigned to the purpose it actually serves, and is not copied onto every specification. The course does not re-teach method validation (PDQC802), peptide HPLC development (PDQC803), specifications and reference standards (PDQC806), MS characterization (PDQC811), or residual solvent and elemental impurity fundamentals (PDQC813). It teaches only the semisolid deltas: - extraction and recovery from waxy, emulsified and polymer-gel matrices; - identification whose specificity is shown in the actual placebo matrix (<3>: a single chromatographic retention time is not specific); - preservative and antioxidant content assay; - Uniformity in Containers and <755> Minimum Fill; - <905> applicability (per <3>, <905> does not apply to emulsions, ointments or gels in single-unit containers for local cutaneous action; confirm exceptions against the current text); - risk-based residual solvent and elemental impurity control, including ICH Q3D(R2) Appendix 5 cutaneous PDEs; - conditional benzene control for carbomer, benzoyl peroxide and hydrocarbon-derived components. Capability on the real lab (3× Agilent 1260 HPLC-DAD, LC-MS/MS triple quad, an unidentified second MS, BacT/ALERT) is treated as conditional. Every test needs an exit route for nonchromophoric, inorganic or poorly extractable analytes, because many monograph actives and functional excipients have no useful UV chromophore. Examples are dimethicone, petrolatum, glycerin and zinc oxide. The physical-test gaps are covered as evidence-based acquisition decisions: - pH (<791>); - apparent viscosity and rheology (<912>, and <1912> yield stress); - polarized-light microscopy; - specific gravity; - water content (<921>); - water activity (<1112>). The course ends with a scored own / buy / outsource decision for every test. Costs come only from written quotes. Contract-lab scopes are produced for GC-HS, ICP-MS, XRPD/DSC and benzene. All USP numerical criteria taught here are drawn from older official editions or FDA copies, and must be confirmed against the current USP-NF before they enter an SOP or specification.

📅 Studied by Skipper on 2026-10-16

📖 Core Concepts

Claude Opus 5.5

Core Concepts: Semisolid Release Testing and Physical Characterization Mapped to the Real Lab

Study notes for Skipper, PDDM912. USP general-chapter numbers, criteria and FDA guidance details below are taken from the course framing and from what I am confident of. Every numeric compendial criterion carries the flag [confirm against current USP–NF / official text]. Treat that flag as a working instruction, not decoration. The same discipline applied to compendial citations in PDQC806 applies here.

1. What this subject is really about

In the PDQC sequence you learned to measure molecules: a lyophilized peptide dissolved cleanly in a diluent, and the main questions were whether the chromatography resolved what mattered and whether the mass balance closed. Semisolid QC breaks one assumption you probably never noticed you were making. The sample is not a solution waiting to be injected. It is an engineered architecture, and the analyte lives inside it.

A cream is a metastable emulsion. Oil droplets are held in a continuous aqueous phase by an interfacial film, and often by a lamellar gel network of fatty alcohol and surfactant. An ointment is a crystalline wax scaffold holding liquid hydrocarbon in its pores, much like a sponge holding oil. A carbomer gel is a packed suspension of swollen, crosslinked microgel particles. Each of these structures does three things to an analyst:

  1. It hides the analyte. Molecules partition into oil droplets, adsorb at interfaces, bind ionically to polyelectrolytes, or sit as crystals occluded in wax. "Is it there?" and "Can I get it out?" are different questions. Recovery is a property of the matrix–method pair, not of the analyte.
  2. It is itself a quality attribute. Viscosity, globule size, specific gravity, pH, water content and water activity are not side notes about a sample that "really" consists of its API. They are the product. A cream with perfect assay that has separated in the tube is a failed product.
  3. It changes with time, temperature and handling. Waxes recrystallize, emulsions coalesce, water escapes through the tube wall, antioxidants are consumed, and preservatives migrate into the oil phase. A semisolid is a slow-moving system, not a fixed object.

The organizing idea of the course follows from this. Every test has to be justified on two axes: what purpose it serves, and what in the matrix could make it lie. The second half of the course title, "mapped to the real lab," adds a third axis: which asset at Peptide Partners can actually run it, under what capability condition, and if none can, who owns it. A test with no owner is a release blocker. Most of the course deliverables are tools for making those owners visible.

An analogy to keep in mind: in peptide QC you were a chemist reading a message. In semisolid QC you are partly a chemist and partly a structural engineer inspecting a building. You still read the message (assay, impurities), but you also have to check that the building is standing (rheology, microscopy, uniformity), that it is not leaking (weight loss), and that the plumbing has not been contaminated (water activity, micro, preservative content).

2. Concept 1 — One attribute, five purposes: the purpose taxonomy

USP <3> Topical and Transdermal Drug Products—Product Quality Tests is the backbone. It organizes tests into three layers [confirm structure against current <3>]:

  • Universal tests: description, identification, assay, impurities. These follow the ICH Q6A logic that <3> cites.
  • Specific tests: uniformity of dosage units, water content (<921>), pH (<791>), apparent viscosity, microbial limits, preservative and antioxidant content, particle size. Each applies where the product's nature makes it relevant.
  • Semisolid-specific tests: Minimum Fill (<755>), apparent viscosity, Uniformity in Containers.

The conceptual move that most people miss is that <3> tells you what attributes matter. It does not tell you when or why you measure them. That question belongs to the purpose taxonomy, and each purpose has its own regulatory anchor and its own logic for acceptance criteria:

PurposeAnchorQuestion answeredHow criteria are set
Development characterizationFDA Q3 guidance for topical products in ANDAs (course cites final March 2026, 10 attributes) [confirm current version]What is this material, structurally?Often no pass/fail. Descriptive, comparative, used to define the design space.
Incoming21 CFR 211.84(d)Is this component lot what it claims to be, and fit for use?Component specification. At least one specific identity test per lot.
In-process control (IPC)21 CFR 211.110Is the process running as designed, right now?Process capability. Fast, actionable, and allowed to be tighter than release.
Release21 CFR 211.165Does this batch conform to its specification?Specification limits justified by data and (for monograph products) by PDDM901 monograph windows.
Stability / comparability21 CFR 211.166; ICH Q1A(R2)Does it stay conforming through shelf life? Is it the same after a change?Shelf-life limits, which may differ from release. Trending.

Worked illustration: apparent viscosity in four roles.

  • IPC: a reading taken after homogenization and cooling. It is a process fingerprint, because emulsion viscosity tracks homogenizer speed, time and cooling rate [Chang et al., 2013, Part II]. The criterion is a narrow window built from pilot batches. The reason to tighten it is to catch a process excursion while correction is still possible.
  • Release: <912> apparent viscosity under fixed conditions, against a specification range.
  • Stability: the same procedure, but the acceptance range has to accommodate legitimate aging drift. That drift is often upward as lamellar networks mature, or downward as emulsions coarsen.
  • Characterization: full flow curves, yield stress, and thixotropy on a rheometer. These usually have no pass/fail. They describe the material well enough that you can judge "sameness" after a scale-up or site change.

Same attribute, four criteria, and potentially two instruments. The per-family test-purpose matrix deliverable exists to make that explicit, cell by cell.

Principle: A test's acceptance criterion is a property of the purpose, not of the attribute. Merging purposes produces either release limits too loose to detect process drift, or IPC limits so tight that normal aging generates OOS results.

3. Concept 2 — The vehicle family determines the test list (and Buhse classification)

Five vehicle families organize the whole course: hydrocarbon ointment, PEG (water-miscible) ointment, o/w cream, lotion, gel. The family changes the test list mainly through one variable, which is the presence of free water.

  • Water-containing families (creams, lotions, aqueous gels) take on pH, water content, water activity, microbial limits and preservative content. Water enables ionization (so pH is meaningful), microbial growth (so a_w, micro and preservatives matter), hydrolysis (a degradant pathway), and evaporative loss (so weight loss on stability matters).
  • Anhydrous hydrocarbon ointments drop most of these. There is no aqueous phase in which to measure pH. a_w is intrinsically low. Water content becomes a check that the product is still anhydrous, not a stability indicator. Microbial risk drops sharply, although it never reaches zero, because spores survive in petrolatum and powders can bring in bioburden.
  • PEG ointments sit in between. They are anhydrous as made, but very hygroscopic. Water uptake through the closure can change consistency and the API's solubility state. Water content can therefore matter on stability even though the product contains no added water.
  • Gels add polymer-specific concerns: carbomer neutralization state, benzene-free grade (Concept 9), and the effect of salt and pH on viscosity.

Why the dosage-form name must be analytically defensible

A monograph product's label must carry a dosage-form name (the course uses an M006.50 labeling example) [confirm the specific monograph citation]. If a dermatologist's specification says "cream" but the product behaves like a lotion, the label is wrong, and that is a misbranding problem, not a matter of taste. [Buhse et al., 2005] offered a decision tree that turns the name into something measurable. Its logic is:

  1. Composition and loss on drying separate ointments from creams. A product with low water-plus-volatiles content (in Buhse's scheme, roughly ≤20% loss on drying) that is mostly hydrocarbon, wax or polyol (roughly ≥50%) classifies as an ointment. Higher water and volatile content points toward cream. [verify the exact thresholds in the paper before writing them into a SOP]
  2. Rheology separates creams from lotions. A lotion flows: its viscosity falls below a threshold that Buhse specified, and a cream does not. [verify the threshold value and measurement conditions; the number is meaningless without the shear conditions]

The beauty here is that a regulatory naming question gets settled with a balance (LOD) and a viscometer. The trap is that the classification is only as good as the measurement conditions. This is the first appearance of a recurring theme: apparent viscosity is only comparable under identical conditions (Concept 7).

4. Concept 3 — The matrix is part of the method: extraction, recovery and representativeness

4.1 Dispersion strategy by family

The analyte has to be moved from a structured matrix into a homogeneous, injectable solution without losing any of it, and without dragging along anything that will foul the column. The strategies follow the physical chemistry of each family:

  • Hydrocarbon ointment: dissolve the hydrocarbon in a nonpolar solvent (hexane, heptane), then back-extract a polar analyte into a polar diluent. This is a liquid–liquid partition step, and its efficiency depends on the analyte's partition coefficient, so it has to be verified per analyte.
  • o/w cream: disperse warm in an organic/aqueous diluent, which melts the waxes and releases droplet contents. Then chill so the waxes congeal and can be removed by centrifugation or filtration. The failure mode is an analyte that co-precipitates with the congealing waxes.
  • Gel: dilute and break down the polymer network. Carbomer viscosity collapses with added salt (charge screening) or with pH shifts that protonate the carboxylates. The failure mode is a cationic analyte that stays ionically bound to the polyanion.

4.2 Recovery, and the spike-then-age insight

Recovery (%) = (amount found in spiked placebo − amount found in unspiked placebo)
               ────────────────────────────────────────────────────────────── × 100
                                    amount spiked

The standard design is to spike API or preservative into placebo across the range, for example 3 levels in triplicate. But spiking just before extraction tests only the extraction. It does not test the binding that develops with time inside the matrix. A freshly spiked analyte sits on the surface. In real product it has had weeks to partition into droplets, adsorb onto the interface, or co-crystallize with wax. Spike-then-age studies (spike, hold under defined conditions, then extract) show whether recovery decays as the analyte equilibrates into the structure. If recovery is 99% at t = 0 and 91% after aging, your method will under-report real product, and the lost 8% will look like degradation on stability. That leads to a false OOS investigation, or worse, a false shelf-life limitation.

The acceptance criterion for recovery comes from the Analytical Target Profile (ATP) established under PDQC802, not from a remembered generic window such as "98–102%." The ATP states the total allowable error for the reportable result. Recovery bias consumes part of that budget.

4.3 Sequential extraction and mass balance (diagnosing occlusion)

When recovery is low, ask: did the analyte degrade, or is it trapped? Sequential extraction answers this.

Total recovered = Σ (amount in extract_i),  i = 1 … n

If Σ plateaus near 100% after n steps → occlusion (extraction-limited)
If Σ plateaus well below 100% and degradant peaks
   account for the deficit                → degradation
If Σ plateaus below 100% and no degradants appear
                                          → irreversible binding, adsorption to
                                            filter or vessel, or volatility loss

Suspended crystals occluded in wax are the classic extraction-limited case. The usual fix is more aggressive dispersion (heat above the wax melting range, longer sonication within a temperature limit), or a solvent that dissolves both the wax and the API.

4.4 Representativeness: sampling depth, sample mass, entrapped air

Before extraction, the sample must represent the container. Two physical realities matter here.

Within-container heterogeneity. Suspensions settle, emulsions cream, and tubes are filled and cooled from the bottom up. A small sample from the tube neck may not represent the tube. The minimum sample mass has to be large enough that the sampling variance is small compared with the specification width. A useful heuristic for suspended particulate APIs, borrowed from sampling theory, is that sampling variance scales inversely with the number of particles in the sample:

RSD_sampling ≈ 1/√N_particles     (Poisson-type limit for discrete particles)

N_particles ≈ (m_sample × w_API) / (ρ_API × v_particle)

  m_sample   = sample mass
  w_API      = API mass fraction
  ρ_API      = API particle density
  v_particle = mean particle volume

This shows that coarse, low-dose suspended actives demand larger samples. It is a scaling relationship for design, not a validated acceptance criterion.

Entrapped air: a counterintuitive point. FDA Q3 item 9 and [Chang et al., 2013] flag entrapped air. You might expect air to "dilute" the assay. For a weight/weight assay it does not. Air has negligible mass, so mg of API per g of product is unchanged. The damage happens elsewhere:

  • Volumetric fills deliver less mass. Fillers meter volume, so aerated product puts fewer grams into each container.
  • Any result expressed per volume (w/v) is biased low.
  • Air pockets create heterogeneity. Weighed sub-samples become erratic and precision suffers.
Worked example (illustrative):
  Deaerated density ρ0 = 1.00 g/mL; entrained air = 5% v/v
  ρ_aerated = ρ0 × (1 − 0.05) = 0.95 g/mL
  Filler set for 30.0 mL → delivers 28.5 g into a "30 g" labeled tube
  Mean fill = 95% of label → fails a "mean ≥ labeled amount" criterion
  (<755>, legacy wording [confirm]), even though w/w assay = 100%

This is why specific gravity (pycnometer or weight-per-gallon cup, at a controlled temperature) doubles as a deaeration IPC. It catches air before it turns into a net-contents failure.

5. Concept 4 — Specificity must be demonstrated in the matrix; identification must be orthogonal

USP <3> states, in substance, that identification "solely by a single chromatographic retention time is not specific." [confirm exact current wording]

Retention time answers "something eluted here." It does not answer "what eluted here." In a clean peptide sample that gap is small. In a cream extract carrying dozens of emollients, fragrance terpenes, surfactant oligomers and their oxidation products, the gap is wide. Orthogonal identification closes it with a second, independent physical property:

  • RT + DAD spectrum match (UV-active analytes on the 1260 HPLC-DAD systems).
  • RT + MRM transition + ion ratio on the triple-quad. This is direct reuse of PDQC811. The ion ratio between a quantifier and a qualifier transition, within a tolerance, works as a molecular fingerprint.

5.1 The specificity package

  1. Placebo (no API, no preservatives)
  2. Placebo + preservatives
  3. Stressed placebo (heat, light, oxidation)
  4. Stressed product

Arm 3 is the one people skip, and it is the most informative. Excipients degrade too. Polysorbates autoxidize into peroxides and aldehydic or acidic fragments. Unsaturated oils oxidize. Fragrance components rearrange. If a stressed-placebo peak co-elutes with an API degradant, your related-substances method will report an "impurity" that belongs to the vehicle, or hide a real one under it.

5.2 Where DAD peak purity breaks down

Peak-purity algorithms compare spectra across a peak. They fail when:

  • the co-eluting interferent is spectrally similar (for example, another conjugated species with an overlapping λmax);
  • the interferent is nonchromophoric (invisible to DAD, so purity looks perfect);
  • baseline drift from lipid carryover distorts the spectra at the peak edges.

Lipid-rich extracts also build up on the column. Hence the matrix-specific hygiene: guard columns, strong-solvent wash steps or wash injections, carryover limits verified after lipid-rich injections, and column-lifetime trending. That last item is a real operating-cost driver which feeds the capacity model.

5.3 Dual-role ingredients: obligations follow classification, not chemistry

Benzyl alcohol is a preservative in one formula and a monograph active in another (the course cites the M017 range of 10–33% [confirm]). Petrolatum, dimethicone and glycerin are excipients or skin-protectant actives (M016 [confirm]) depending on concentration and claim. The molecule is the same, but the analytical obligation is completely different. As an active, it needs labeled-strength assay with monograph windows. As an excipient, it needs identity at receipt and possibly content testing if it serves a functional role, such as a preservative. The PDDM901 classification output decides. A chemist cannot settle this question from the bench.

6. Concept 5 — Analytical exits: what to do when HPLC-DAD cannot see it

The triage tree is short to state and hard to execute:

Analyte
 ├─ UV chromophore AND extractable with demonstrated recovery
 │     → HPLC-DAD (owned)
 ├─ Ionizable / ionizes in ESI, weak or no UV
 │     → LC-MS/MS (owned) — manage matrix effects:
 │        isotope-labelled internal standard or matrix-matched calibration
 ├─ Neither (nonchromophoric neutral organics; inorganics)
 │     → alternative technique (not owned → buy or contract)
 └─ No validated route in-house or at a qualified CTL
       → product FAILS the PDDM925 technology-transfer gate

Matrix effect for LC-MS/MS, quantified the standard way:

ME (%) = (slope of matrix-matched calibration / slope of solvent calibration − 1) × 100

ME < 0 → ion suppression;  ME > 0 → enhancement

Surfactants and phospholipids are notorious ESI suppressors, and creams are full of surfactants.

The awkward truth is that the most common skin-protectant actives are the hardest to measure. Petrolatum, dimethicone, mineral oil, glycerin and fatty alcohols have no useful chromophore. Candidate exits include CAD or ELSD detectors, GC, FTIR, and gravimetric approaches. All are unowned or unverified, and each must be checked against current compendial methods [verify]. Inorganic monograph actives (zinc oxide, calamine, titanium dioxide, kaolin, zinc salts) point toward compendial titrimetry (complexometric EDTA titration of zinc is the classical route [verify current monograph method]), ICP-OES/MS through a contract lab, or XRF or ashing approaches [verify]. The decision trigger is concrete: the first time a dermatologist specification names one of these as the labeled active, the exit has to exist.

7. Concept 6 — Content is not efficacy: partitioning, pH and preservatives

This is one of the most important and most counterintuitive ideas in the course. A preservative assay measures total content. Microbes, however, live in the aqueous phase, and only the preservative free in the water acts on them.

For a simple oil/water system with no micellar binding:

f_w = 1 / (1 + K·φ)

  f_w = fraction of total preservative free in the aqueous phase
  K   = oil/water partition coefficient (C_oil / C_water) for the actual oil
  φ   = V_oil / V_water (phase-volume ratio)

With surfactant micelles (solubilizing capacity R = C_micelle / C_water):
f_w ≈ 1 / (1 + K·φ + R)

Illustrative numbers (not real data): with φ = 0.25 (20% oil) and K = 8, f_w = 1/(1 + 2) = 0.33, so two-thirds of the "assayed" preservative is in the oil. The empirical finding the course cites from a lecithin emulsion study makes the same point: only 17–31% of methylparaben and 2.3–6% of propylparaben were free in water. Propylparaben is the more lipophilic of the pair and is affected far more. A total assay of 100% of target can coexist with an aqueous concentration below the effective threshold.

Consequences for specifications:

  • The preservative content limit has to be tied to <51> antimicrobial effectiveness results (PDDM913). The lowest content shown to pass AET is the scientific basis for the stability lower limit. Release limits sit above it to allow for loss on aging (study design in PDDM924).
  • pH-dependent preservatives need a paired pH specification. Weak-acid preservatives act mainly in the undissociated form. Henderson–Hasselbalch gives the active fraction:
f_undissociated = 1 / (1 + 10^(pH − pKa))

Sorbic acid, pKa ≈ 4.76:
  pH 4.5 → 1/(1 + 10^(−0.26)) = 1/(1 + 0.55) ≈ 0.65
  pH 5.5 → 1/(1 + 10^(0.74))  = 1/(1 + 5.5)  ≈ 0.15
  pH 6.5 → 1/(1 + 10^(1.74))  = 1/(1 + 55)   ≈ 0.02

A one-unit pH drift on stability can cut the active preservative fraction by about four-fold while the total sorbate assay stays unchanged. That is why sorbate and benzoate content specifications travel with pH specifications. (The course's "effective below about pH 6" heuristic is flagged unverified. The equation shows that the decline is continuous rather than a cliff.)

Other points from this concept:

  • EDTA has no useful UV chromophore. It needs a Concept 5 exit, commonly HPLC after metal complexation (e.g., Fe³⁺ or Cu²⁺ complex) [verify the approach for the matrix].
  • Antioxidants are designed to be consumed. A falling BHT, ascorbate or sulfite level is a stability-indicating signal, an early warning that appears before API oxidation degradants do. Trend it and track it alongside the degradants, using PDQC803 stability-indicating principles adapted to the matrix.

8. Concept 7 — Rheology: apparent viscosity versus material characterization

Semisolids are non-Newtonian, so "viscosity" is not one number. It is a function of shear rate, time and temperature. A common descriptive model is Herschel–Bulkley:

τ = τ0 + K·γ̇ⁿ        (for τ > τ0; below τ0 the material does not flow)

  τ  = shear stress (Pa)
  τ0 = yield stress (Pa)
  K  = consistency index (Pa·sⁿ)
  γ̇  = shear rate (s⁻¹)
  n  = flow-behavior index (n < 1: shear-thinning / pseudoplastic)

Apparent viscosity:  η_app(γ̇) = τ / γ̇ = τ0/γ̇ + K·γ̇^(n−1)

Read the apparent-viscosity expression closely, because it explains the whole viscometer-versus-rheometer debate. η_app depends on γ̇. Change the spindle, the speed or the geometry and you change γ̇, which means you measure a different number for the same material. This is why <912> results are only comparable under identical spindle, speed, temperature, equilibration time and reading time. It is also why a viscosity specification has to state all five.

8.1 The two instruments answer different questions

  • Rotational viscometer (<912>): a single-point apparent viscosity for release and IPC. Helipath T-bar spindles move down through a non-flowing cream so the bar always cuts fresh material, avoiding "channeling," where the spindle spins in a hole it has dug. The cost is that the shear field is undefined, so the number is a reproducible index rather than a material property. Small-sample adapters give better-defined geometry with less material.
  • Rheometer (<1911>, <1912>): defined geometries (cone-plate, parallel plate) yield real material functions. These include flow curves; yield stress (<1912>); thixotropy, measured as the hysteresis loop area between up- and down-ramps; and oscillatory sweeps. In oscillation, G′ (storage modulus, elastic) and G″ (loss modulus, viscous) describe structure without destroying it. When G′ > G″ across the linear viscoelastic region, the material behaves as a structured solid at rest. That is what you want in a cream that should not run out of the jar.
Thixotropic index (loop area):  A = ∫ τ_up dγ̇ − ∫ τ_down dγ̇
Loss tangent:                   tan δ = G″ / G′   (< 1 → solid-like; > 1 → liquid-like)

8.2 Behavior by vehicle

  • Carbomer gels are pseudoplastic yield-stress materials built from swollen microgel particles. A surprising and useful finding of [Islam et al., 2004] is that their rheology changes little between about pH 5.0 and 8.0. Once neutralization has swollen the microgels to close packing, further pH changes in that window add little. The practical implication is that a pH specification for a carbomer gel is not mainly a viscosity-protection specification in that range. Its justification comes from API stability, preservative function and skin compatibility. Outside that window, especially at low pH where neutralization is incomplete, viscosity can collapse.
  • Emulsions carry their process history in their rheology. Homogenizer speed, time and cooling rate set droplet size and the structure of the lamellar network [Chang et al., 2013, Part II], which is why viscosity serves as a process-signature IPC. [Brummer, 2006] develops the link between emulsion microstructure and rheology in depth and is the reference to read for interpreting oscillatory data.

8.3 Setting acceptance ranges

The ranges have to come from development and pilot data plus observed stability drift. There are two symmetric failure modes:

  • Too wide: the test cannot distinguish a good batch from a broken one. It becomes compliance theater.
  • Too narrow: normal variation (measurement precision plus true batch variability plus aging) generates OOS results. Each one triggers a PDQC801 investigation that ends in "no assignable cause," which erodes trust in the whole system.

A useful sanity check: the range should be several times the method's intermediate-precision SD and should still exclude the viscosity of a deliberately mis-processed batch, such as one with under-homogenization or a crash-cooling deviation.

Decision for the real lab: a rotational viscometer is the minimum needed to meet <3>. A rheometer is justified when development characterization, scale-up comparability (PDDM921) or Q3-type sameness work is in scope. Score both on purpose coverage, throughput, operator skill and qualification burden.

9. Concept 8 — Uniformity in Containers, Minimum Fill and the <905> determination

These three procedures answer three different questions, and confusing them is a common audit finding.

ProcedureQuestionUnit tested
Uniformity in Containers (<3>)Is the product the same throughout the container? (Detects phase separation and settling.)Top / middle / bottom portions of a tube or jar
<755> Minimum FillDoes the container hold at least what the label says?Net contents of multiple containers
<905> Uniformity of Dosage UnitsDoes each discrete dose contain the right amount?Individual dosage units

9.1 Uniformity in Containers [confirm all values against current <3>]

  • Sample top, middle and bottom portions. For tubes, cut the tube open to reach the portions. For jars, core the product.
  • For tubes ≥5 g, stage 1 takes 3 portions from 1 tube. The within-tube maximum difference must be NMT 10.0%.
  • A staged extension goes to 3 tubes if stage 1 fails.
Within-container difference (one common formulation; confirm the <3> definition):
  D = (max portion assay − min portion assay) / mean portion assay × 100%

For pumps and airless dispensers, <3> directs you to prime as instructed and then collect the next dispensed material. Prime-weight variability is a confounder: inconsistent priming changes which part of the reservoir you sample.

9.2 <755> Minimum Fill (legacy criteria [confirm current text])

  • Test 10 containers. The mean net content must be ≥ the labeled amount.
  • Each container must be ≥90% of label for labels ≤60 g, or ≥95% for labels >60–150 g.
  • If the test fails, test 20 additional containers.

Practice points: empty-tare technique (weigh full, empty and clean each container, rather than assuming a mean tare), and a balance qualified for the minimum weight (PDQC805). Net contents also falls under NIST Handbook 133 controls, which are handed off to PDDM923.

9.3 The <905> applicability determination

Per <3>, <905> does not apply to emulsions, ointments or gels in single-unit containers intended for local cutaneous action. It applies to transdermal systems, systemically acting products, or single-unit packets that need tight dose control. When <905> is applied, <755> is not required [confirm all three statements against current <3>]. The determination memo template should therefore:

  1. cite the current <3> text by official date;
  2. state the container type (multi-use tube or jar vs single-use packet);
  3. state the intended action (local cutaneous);
  4. flag single-use packets as the likely exception requiring explicit justification.

10. Concept 9 — pH, water and weight loss: measurements that depend on how you ask

10.1 pH (<791>): the dilution problem

<791> specifies measurement at 25 ± 2 °C unless otherwise stated [confirm]. In a semisolid there are two approaches:

  • Direct measurement with a spear or flat-surface electrode. This measures the product as is, but a lipid-rich surface fouls the junction and the glass membrane, so it needs a strict cleaning and verification routine (for example, a buffer check after every N samples).
  • A defined dilution (e.g., 1:10 in water). This is more reproducible, but dilution changes the result. Ionic strength drops, activity coefficients change, buffer capacity is diluted, and for weakly buffered products the diluent's own pH and dissolved CO₂ pull the reading.
For a buffer HA/A⁻:  pH = pKa' + log([A⁻]/[HA])
  where pKa' depends on ionic strength via activity coefficients
  (Debye–Hückel: log γ ≈ −0.51·z²·√I / (1 + √I) at 25 °C)
Dilution reduces I → shifts pKa' → shifts the measured pH even though
the [A⁻]/[HA] ratio is unchanged.

Rule: the procedure must fix the ratio, the diluent (with stated quality and CO₂ handling) and the temperature. A pH specification without those conditions is not a specification. pH applies to aqueous families as IPC, release and stability, and does not apply to anhydrous ointments. The pH meter is currently missing from the asset list, so the URS has to cover temperature compensation, data capture and audit trail, with Part 11 handled for a standalone instrument through PDQC814.

10.2 Water content (<921>)

  • KF oven method: the sample is heated and water is carried by dry gas into the titration cell. The wax matrix never reaches the cell, which avoids fouling and side reactions. This is the elegant solution for ointments and wax-rich creams. Oven temperature must be high enough to release water but low enough to avoid decomposing components that release water.
  • Direct KF with solubilizers (e.g., chloroform or long-chain alcohols in the working medium) to disperse the matrix.
  • LOD or a moisture balance as a surrogate. These measure all volatiles. Ethanol, isopropanol and propylene glycol all leave, so LOD overstates water in exactly the products where volatiles are part of the formula. This is the same reason LOD and KF diverge, and why Buhse uses "water plus volatiles" rather than water alone.

10.3 Weight loss in semi-permeable containers

Plastic and laminate tubes and airless pumps are permeable to water vapor. Under ICH Q1A(R2) §2.2.7.3, a 5% loss in water from initial value after the equivalent of 3 months at the low-RH accelerated condition is a significant change [confirm exact conditions in Q1A(R2)].

Weight loss (%) = (W_initial − W_t) / (W_initial − W_tare) × 100      (net product basis)

Water-loss % (relative to initial water) ≈ ΔW_net / (W_net,initial × x_w,initial) × 100
  x_w = initial water mass fraction

Example: 30 g net cream, 60% water → 18 g water.
  A 5% water-loss significant change = 0.9 g, i.e. 3.0% of net product mass.

The insight: for a water-rich cream, the significant-change threshold expressed as product weight loss is smaller than 5%. Write the stability procedure in terms of water, not gross mass, or you will under-call significant change. Execution belongs to PDDM924. This week only defines the analytical procedure.

11. Concept 10 — Physical characterization: microscopy, specific gravity, water activity, solid state

11.1 Polarized-light microscopy

Under crossed polarizers, isotropic liquids (oil droplets, water) appear dark. Birefringent crystals (most crystalline APIs, crystalline wax domains) and anisotropic liquid-crystalline lamellar phases (characteristic "Maltese crosses" around droplets) light up. Its uses here:

  • globule size and coalescence trending;
  • detecting API recrystallization on cooling. An API dissolved hot can supersaturate and nucleate as the batch cools [Chang et al., 2013, Part I; published online 2012];
  • particle size of suspended actives;
  • an IPC for setting homogenization speed and time.

Microscopy becomes data rather than anecdote only with a calibrated reticle (stage micrometer), a predefined field-sampling plan (no "representative field" chosen after looking), and image retention as raw data (PDQC814).

11.2 Water activity (<1112>)

a_w = p / p0     (vapor pressure of water over the sample / over pure water, same T)
     = ERH / 100 (equilibrium relative humidity)

Water content tells you how much water there is. Water activity tells you how available it is. Glycerin, propylene glycol, sorbitol and salts bind water and lower a_w, so a product can be 40% water and still be hostile to growth. The growth limits cited in the course [confirm against current <1112>]:

  • a_w 0.91: P. aeruginosa, E. coli, Salmonella
  • a_w 0.86: S. aureus
  • a_w 0.77: A. niger
  • a_w 0.60: no microbial proliferation

Low a_w can support a reduced microbial-testing rationale (co-authored with PDDM913). It is a risk argument, not an automatic exemption.

11.3 Solid state and structure (Q3 items 2–4)

Polymorphic form, phase states and structural organization are characterization only. XRPD and DSC are outsourced under a contract scope. Treat the polymorph risk as real when the API is suspended (crystals are present and can convert) or dissolved hot and cooled (supersaturation can nucleate a different form). A fully dissolved API at well below saturation carries little solid-state risk.

11.4 The full Q3 list as a checklist

Appearance and texture, phase states, structure, polymorph, rheology, a_w and drying rate, pH and buffering, oleaginous components, specific gravity, and metamorphosis on dispensing. The Q3 guidance is written for ANDAs. For monograph products it is a characterization checklist, not a filing requirement. It is still the most complete statement of what "the structure is the product" means.

12. Concept 11 — Impurities by risk: excipient-driven degradation, solvents, elements, benzene, DEG/EG

For a peptide API, impurities come mostly from synthesis. For a semisolid with 10–20 components, most impurity risk enters through the excipients, which flips the analytical emphasis.

  • Peroxides from polysorbate autoxidation (catalyzed by Fe²⁺ and H₂O₂) oxidize susceptible APIs. Note the parallel with methionine oxidation in peptides.
  • Photolysis, including visible-light sensitivity in translucent gels.
  • API–preservative interactions.
  • Placebo-subtraction rules: excipient peaks seen in the placebo are excluded from impurity totals only when identity is demonstrated by the specificity package (Concept 4). Never exclude them on retention time alone.

12.2 Residual solvents (<467>) and elemental impurities (ICH Q3D(R2) App. 5, <232>/<233>)

Both use a component-based approach: supplier declarations and CoAs feed a risk assessment, and testing is triggered by risk or by a supplier gap. For elemental impurities, the product-level check sums the component contributions:

C_product,E = Σ_k ( w_k × C_k,E )

  w_k    = mass fraction of component k in the formula
  C_k,E  = concentration of element E in component k (supplier data or test)

Compare C_product,E (or the derived daily exposure) with the cutaneous PDE-derived
limit for element E from Q3D(R2) Appendix 5 [verify the PDE values and any
cutaneous-specific provisions for sensitizing elements in the current text].
The product-amount assumption used to convert PDE → concentration comes from the
product dossier; it is a regulatory calculation input, not a use instruction.

Inorganic actives (ZnO, calamine, TiO₂, kaolin, talc) and mined mineral excipients dominate the sum [verify element-specific risks from supplier data]. Confirmatory ICP-MS under <232>/<233> is outsourced. When the assessment justifies "no routine test," the control strategy must state a periodic-verification frequency and the re-assessment triggers: new supplier, new grade, new inorganic active.

12.3 Benzene and DEG/EG: the high-consequence conditional tests

  • Carbomer: use only benzene-free grades, with the specification referencing the post-omission USP carbomer monographs and benzene ≤2 ppm (the ICH Q3C Class 1 limit as applied), per the FDA carbomer guidance (Dec 2023). That guidance applies to topical creams, gels, lotions and ointments, including OTC monograph drugs.
  • Other benzene triggers per the FDA alert: hydrocarbon-derived components (e.g., isobutane propellant) and active degradation (benzoyl peroxide). In FDA testing of 95 BPO products (Mar 2025), most had undetectable or very low benzene, followed by a limited number of retail-level recalls. The temperature dependence of BPO-to-benzene conversion is flagged unverified in this course, so stability-time-point benzene testing must be justified from data, not assumed.
  • DEG/EG: for high-risk components (glycerin, propylene glycol, sorbitol solution, etc.), the USP–NF limit test (NMT 0.10%) applies to each shipment of each lot as part of identity, per the FDA DEG/EG guidance (May 2023, Rev. 1). It is a GC method. With no GC in-house, the choice is to outsource or buy a GC [verify the instrument requirements of the current USP–NF method].

Every benzene determination needs headspace GC with suitable detection, which is not owned. The contract scope must cover matrix-specific validation or verification, an LOQ well below 2 ppm, volatile-loss-proof sample handling, and chain of custody. Each product dossier receives a decision record: benzene risk = negligible / controlled by component / requires product testing.

12.4 Incoming testing: the most-cited failure

21 CFR 211.84(d) requires at least one specific identity test on every component lot, active or inactive. A CoA can replace other tests only after the supplier's results have been validated at intervals. The course identifies this as the most-cited finding in the 2025 OTC topical warning letters. With 10–20 components per batch, the identity workload is mostly an excipient problem. FTIR (not owned) is the common identity route for waxes, petrolatum, dimethicone and polymers, which makes it a gap to score in week 14.

13. Concept 12 — Capability conditions: mapping tests to the real lab

"We have an HPLC" is not a capability claim. A capability claim is conditional:

  • HPLC-DAD: yes, if the analyte has a chromophore and recovery is shown in this matrix and the LOQ is below the reporting threshold and throughput fits the batch cadence.
  • LC-MS/MS: confirmation and low-level residues only. Routine high-level assay by MS invites matrix-effect variability you don't need.
  • BacT/ALERT: not applicable to <61> counts or <51> log reductions. It is presence/absence only, and the micro scope goes to PDDM913.
  • Second MS: model unknown → every purchase decision that depends on it is frozen. If it is a GC-MS, it could unlock volatile extractables and, with a headspace sampler, residual solvents or benzene. Until it is identified, nothing can be assumed.

The capacity model turns the matrix into hours and people:

Instrument-hours/yr (asset j) = Σ_families Σ_tests [ B_f × n_samples,t × (t_run,t + t_prep,t) ] × (1 + r_repeat)

Analyst FTE = Σ (hands-on hours) / (available productive hours per FTE per year)

  B_f       = projected batches/yr in family f
  r_repeat  = allowance for system-suitability failures, reinjections, investigations

These outputs feed the week 14 own/buy/outsource scorecard. That scorecard uses capital and operating costs from written quotes only, because estimated price bands do not survive a QU panel.

14. Connections to Peptide Chemistry

Much of this course reuses ideas you already own, transposed into a new matrix:

  • Mass balance and content accounting (PDQC812). In peptide QC, net peptide content required accounting for counter-ion, water and impurities before the numbers closed. Here, sequential-extraction mass balance (Concept 3) is the same intellectual move. When recovery is low, account for every gram before blaming degradation.
  • Adsorptive losses. Peptides stick to glass, filters and plastic. Cationic, amphiphilic peptides are the worst offenders. The semisolid version is filter adsorption of lipophilic preservatives and APIs, and ionic binding to carbomer. If a dermatologist's formula ever puts a cationic peptide into a carbomer gel (cosmetic "signal peptides" are common in skin products, and PDDM901 would decide whether such an ingredient has drug or cosmetic status), expect polyanion–polycation complexation. Recovery would then need high ionic strength or pH manipulation to break it. That is the PDQC peptide-recovery problem in a harsher matrix.
  • Interfacial partitioning. Lipidated peptides (palmitoyl conjugates) are amphiphiles, and they will accumulate at the oil–water interface exactly as parabens do. "Content is not availability" (Concept 6) applies to them in full.
  • Oxidation chemistry. Polysorbate-derived peroxides that oxidize an API are the same species that oxidize methionine and tryptophan in peptide formulations. The specificity logic from PDQC803 carries over directly: stress the placebo as well as the product.
  • Orthogonal identity (PDQC811). MRM transitions with ion-ratio tolerances, which you used for peptide sequence support, are the same tool <3> asks for when retention time alone is insufficient.
  • Higher-order attributes (PDQC815). Aggregation in peptides and coalescence or recrystallization in semisolids are both slow, structure-level changes that a primary-structure assay cannot see. You need a physical method (SEC or DLS there; microscopy, rheology or XRPD here) to catch them.
  • Thermodynamics of metastability (BCHM603). A folded protein is kinetically trapped in a free-energy minimum, and so is an emulsion. Both age toward lower free energy (unfolding or aggregation; Ostwald ripening or coalescence), and both are characterized by measuring how close they sit to the edge. For proteins that measure is Tm. For emulsions it is the linear viscoelastic limit or the yield stress.

15. Common misconceptions to watch out for

  1. "An attribute has one acceptance criterion." No. Criteria belong to purposes. IPC, release and stability limits for the same attribute can, and often should, differ.
  2. "Good spike recovery means the method recovers real product." Only if the analyte had time to equilibrate into the matrix. Run spike-then-age.
  3. "Entrapped air dilutes the assay." Not for a w/w assay. It damages fill mass, w/v results and sampling precision.
  4. "Retention time plus a clean DAD purity flag proves identity." Purity algorithms cannot see nonchromophoric or spectrally similar co-eluters, and <3> explicitly rejects retention time alone.
  5. "Preservative assay at 100% means the product is protected." The free aqueous fraction and the pH-dependent undissociated fraction determine efficacy. Link content to <51>.
  6. "Viscosity is a number." Apparent viscosity is a number at a shear condition. Change the spindle or speed and you have changed the measurement.
  7. "pH of a cream is a property of the cream." It is a property of the cream plus the procedure. Diluted and direct readings differ, and the ratio and diluent must be fixed.
  8. "LOD equals water content." LOD counts every volatile. Propylene glycol and alcohols bias it upward.
  9. "5% weight loss is the significant-change trigger." Q1A(R2) speaks of 5% loss of water. For a 60%-water cream that is about 3% of product mass.
  10. "<905> content uniformity applies to every dosage form." Per <3>, it generally does not apply to locally acting emulsions, ointments and gels in single-unit containers. Packets are the exception to assess.
  11. "Low water content means low microbial risk." Water activity, not content, governs growth. Humectants can make a watery product hostile, and a "dry" one can still have damp microdomains.
  12. "A CoA is enough for excipients." 21 CFR 211.84(d) requires a specific identity test on every lot of every component. High-risk polyols need DEG/EG testing as part of identity.
  13. "Benzene is only a carbomer problem." Hydrocarbon-derived propellants and BPO degradation are also FDA-named triggers. The decision record has to address each.
  14. "Owning an HPLC means we can test it." Capability is conditional on chromophore, recovery, LOQ and throughput. A test without a qualified owner, in-house or at a CTL, blocks release.

Final reminder to self: in this course, a missing "[confirm against current USP–NF]" flag on a compendial number is itself a defect. The panel in week 14 will ask "where did that number come from, and as of which official date?" before asking anything else.

⚙️ Mechanisms & Applications

GPT-6 Astra

Mechanisms & Applications

Skipper’s central insight: a semisolid is not simply an API dissolved in a thick vehicle. It is a manufactured arrangement of phases, interfaces, particles, polymers, and sometimes trapped air. Its quality depends on both what is present and how that material is organized. HPLC can establish composition while completely destroying the organization that determines dispensing, physical stability, and drug release.

This is the important extension of my protein-science training: just as a correct amino-acid composition does not establish correct folding, a correct API assay does not establish a correctly structured cream. But the analogy has a limit: unlike a protein sequence, a semisolid formula often permits several metastable structures, selected by mixing, cooling, aging, and packaging history. Release testing must detect the structural differences that matter without turning every development experiment into a routine release requirement. [1–4]

Source-control rule: the procedures below are scientific frameworks, not substitutes for current official methods. Verify all USP acceptance values, sampling stages, exceptions, and chapter cross-references against the current USP–NF before issuing an SOP. Verify the current final FDA Q3 guidance and its exact attribute terminology before using it in a regulatory dossier. No numerical training example below represents an executed experiment at Peptide Partners.

1. From product classification to a defensible test: the control-strategy mechanism

  1. Establish the legal and technical product identity. Inherit the active ingredient, strength, claims, route, and dosage-form determination from PDDM901. An ingredient’s chemical identity does not determine its regulatory role: the same material can be an excipient in one product and an active ingredient in another.
  2. Identify the physical architecture. Is the API dissolved, suspended, or distributed between phases? Is water continuous, dispersed, or absent? What provides structure: crystalline wax, PEG, packed droplets, or a swollen polymer network?
  3. Translate architecture into failure mechanisms. Examples include crystal growth, droplet coalescence, polymer collapse, oxidation, preservative sequestration, solvent loss, and separation within the package.
  4. Select an attribute that detects each consequential failure. Examples include microscopy for crystal growth, spatial assay for segregation, rheology for network change, and stability-indicating chromatography for chemical degradation.
  5. Assign the test a purpose. Development characterization, incoming control, IPC, release, and stability/comparability are different decisions—even when they measure the same attribute.
  6. Assign the method, criterion, owner, and contingency. A test without a qualified instrument or qualified contract laboratory is an unresolved control-strategy gap, not a future administrative detail.

USP <3> supplies the product-quality framework. Incoming component controls arise separately under 21 CFR 211.84(d), laboratory controls under 211.160, and finished-product testing under 211.165. FDA Q3 characterization for topical ANDAs informs structural understanding; it is not automatically a release-testing mandate for an OTC monograph product. [5,6]

  • Hydrocarbon ointment: prioritize identity, assay and impurities as applicable, fill, consistency, suspended-particle attributes, and spatial uniformity where justified. Direct aqueous pH is generally not meaningful. Low water availability may reduce microbial risk, but does not erase the obligation to assess it.
  • PEG ointment: examine hygroscopicity, PEG molecular-weight distribution or grade, water uptake, crystallization, and temperature-dependent consistency. “Water-soluble base” does not necessarily mean “water-containing formulation.”
  • Oil-in-water cream: add continuous-phase pH, droplet structure, rheology, water balance, preservation, and microbiological controls.
  • Lotion: often has lower consistency and greater sedimentation or creaming susceptibility. Do not assume every lotion is an oil-in-water emulsion; establish the actual architecture.
  • Gel: establish the gelling mechanism. Aqueous carbomer gels require different pH and ionic-strength controls from organogels or thermoreversible gels.

Buhse and colleagues’ topical-classification work matters because dosage-form names were not always consistently connected to measurable properties. Their composition and physical-property approach helps test whether “cream,” “lotion,” or “ointment” is scientifically defensible. It does not authorize changing a required label designation without checking the applicable regulatory requirements. [7]

2. Extracting an analyte: deliberately dismantling the dosage form

In peptide QC, I learned that adsorption, incomplete dissolution, and matrix effects can invalidate a beautiful chromatogram. Semisolids add a further obstacle: an analyte can be physically trapped behind wax, partitioned into oil, associated with surfactant micelles, or bound within a polymer network.

The mechanism has four stages: release the analyte from its local environment, transfer it into the analytical solvent, separate interfering bulk matrix, and demonstrate that these operations have not changed the analyte.

  1. Take a representative mass. Define the sampling location, minimum sample mass, and any permitted homogenization. Homogenization is appropriate for some composite assays but would destroy the evidence needed for a within-container uniformity test.
  2. Disrupt the relevant structure.
    • For petrolatum ointment, screen nonpolar dissolution followed by selective extraction into a compatible polar phase.
    • For an oil-in-water cream, screen controlled warming and organic/aqueous dispersion, followed by cooling and centrifugation to remove congealed lipids.
    • For a polymer gel, screen dilution and controlled pH or ionic-strength changes that reduce network resistance without precipitating or degrading the analyte.
  3. Control energy input. Sonication and warming improve transport, but can accelerate oxidation or hydrolysis. Define temperature and exposure time rather than instructing an analyst to “sonicate until dissolved.”
  4. Separate without selective loss. Evaluate centrifugation and filtration. Compare filter materials against an appropriate unfiltered or centrifuged reference; assess adsorption, extractables, and analyte stability.
  5. Challenge extraction completeness. Re-extract the retained matrix, compare alternative extraction routes, and investigate residual analyte. A clean first extract is not proof of quantitative recovery.

For a simplified equilibrium extraction, let K be the concentration ratio between the extracting solvent and the original phase. The remaining fraction after one extraction is:

K = Cextracting phase / Coriginal phase

Fraction remaining, q = Voriginal / (Voriginal + K Vextracting)

After n extractions with fresh equal solvent portions:
Fraction remaining = q^n
Fraction recovered = 1 − q^n

Illustrative calculation: if K = 4, the original phase is 10 mL, and each fresh extraction uses 10 mL, one extraction recovers 80%; two recover 96%; three recover 99.2%. These predictions fail if the analyte is kinetically trapped, the phase volumes change, emulsions persist, or chemical degradation occurs. Partition theory is a starting hypothesis—not a recovery certificate.

The training study should compare three extraction schemes in each of two purchased bases: white petrolatum and an oil-in-water cream. A UV-active surrogate and a paraben pair provide contrasting partitioning behavior. Include placebo, pre-extraction spikes, post-extraction spikes, and aged spikes. No semisolid manufacturing capability should be inferred from this purchased-base exercise.

Recovery (%) =
[(measured amount in spiked sample − native amount) / amount added] × 100

RSD (%) = 100 × standard deviation / mean

Three levels in triplicate are a useful feasibility design, but acceptance criteria must come from the analytical target profile and intended decision. A freshly added spike may remain on accessible surfaces, whereas native API may have crystallized inside wax or equilibrated into a different phase. Therefore, good fresh-spike recovery can coexist with poor recovery of manufactured product.

For LC–MS/MS, separate extraction recovery from ionization effects:

Using matched concentrations and appropriate response normalization:

Matrix factor = response of post-extraction spike / response in neat solution

Extraction recovery = response of pre-extraction spike /
                      response of post-extraction spike

Overall process efficiency = response of pre-extraction spike /
                             response in neat solution

This distinction is especially relevant to low-level impurities and peptide-containing topical matrices: loss during extraction and suppression in the ion source require different corrective actions.

3. Identification and assay: making the detector answer the right question

Chromatographic retention is a behavior, not a unique molecular identity. Different compounds can share a retention time. USP <3> specifically cautions against identification solely by a single chromatographic retention time. A matrix-specific identification package must demonstrate discrimination from plausible alternatives. [5]

  1. Establish chromatographic separation. Inject diluent, placebo, preservative-containing placebo, reference material, and product.
  2. Add a second identifying dimension. For a suitable chromophore, combine retention behavior with a DAD spectrum. For an appropriate ionizable analyte, combine retention behavior with validated precursor/product-ion transitions and ion-ratio criteria.
  3. Challenge the actual matrix. Examine stressed placebo and stressed product under justified heat, light, and oxidative conditions. A new excipient-derived peak can be more important than a familiar API degradant.
  4. Investigate unresolved ambiguity. Change chromatographic selectivity or obtain orthogonal structural evidence. DAD peak-purity software and a single MRM transition do not prove absence of coelution.

Peptide Partners’ three Agilent 1260 HPLC-DAD systems are strong candidates for UV-active APIs, preservatives, antioxidants, and suitable degradants—if extraction, specificity, sensitivity, stability, and throughput are established. They are not universal ingredient analyzers.

  • Weakly absorbing but ionizable organic analyte: evaluate LC–MS/MS, including matrix effects, carryover, calibration, and internal-standard suitability.
  • Nonchromophoric organic material: evaluate the applicable compendial approach and techniques such as FTIR, GC, charged-aerosol detection, ELSD, or a justified chemical assay. These are not interchangeable.
  • Inorganic active: consider validated titration or outsourced elemental analysis. Total zinc, for example, does not by itself distinguish zinc oxide from another zinc-containing species.
  • Poorly extractable particulate active: demonstrate dissolution or digestion completeness and chemical specificity before selecting the detector.

For wax-rich injections, include guard-column strategy, strong washes, carryover checks after challenging samples, and column-lifetime trending. Matrix burden is both a scientific risk and an operating-cost driver.

4. Preservative content versus preservative availability

A surprising result: a cream can pass total preservative assay and still have inadequate preservation. The total amount is distributed among aqueous phase, oil phase, interfaces, micelles, and sometimes package surfaces. These locations are not microbiologically equivalent.

Total preservative =
aqueous free + oil-associated + interface/micelle-associated
+ other bound or sorbed fractions

For a weak-acid preservative, pH adds another equilibrium. Using sorbic acid with an approximate aqueous pKₐ of 4.76:

Fraction undissociated =
1 / [1 + 10^(pH − pKₐ)]

At pH 4.76: fraction ≈ 0.50
At pH 6.00: fraction ≈ 0.054

This is not a binary “effective below pH 6” rule. The undissociated fraction changes continuously, and actual performance also depends on organism, partitioning, ionic strength, formulation, and exposure conditions. Apparent pKₐ and activity behavior can differ in complex media.

  1. Measure total preservative with a validated matrix-specific assay.
  2. Control pH where it affects preservative availability or activity.
  3. Demonstrate antimicrobial effectiveness under USP <51> using the appropriate method and neutralization/recovery controls.
  4. Challenge relevant formulation boundaries, including preservative level, pH, and aging.
  5. Set a justified shelf-life lower limit supported by efficacy data, analytical uncertainty, and expected drift—not simply the lowest concentration that happened to pass one experiment.

This is closely related to free-versus-bound drug concepts in biochemistry: total concentration is often a poor proxy for the concentration accessible to a biological target. Nevertheless, a calculated free fraction cannot replace antimicrobial effectiveness testing. BacT/ALERT’s presence/absence output cannot provide USP <51> quantitative log reductions or USP <61> enumeration.

5. Rheology: measuring structure through deformation

Rheology asks how a material stores and dissipates mechanical energy. A single viscosity result is one point on that response, under one history. Semisolids often “remember” prior mixing, filling, shaking, and sampling.

Newtonian relation:
τ = η γ̇

Apparent viscosity:
ηapp = τ / γ̇

Herschel–Bulkley model, in the yielded region:
τ = τy + K γ̇^n

τ = shear stress
γ̇ = shear rate
τy = model yield stress
K = consistency coefficient
n < 1 indicates shear thinning

A yield stress is not a perfectly instrument-independent material constant for every structured semisolid. Its reported value depends on the model, measurement window, history, and operational definition.

  1. Standardize loading. Avoid unnecessary working, bubbles, evaporation, and unequal waiting times.
  2. Control temperature. Temperature changes continuous-phase viscosity, wax crystallinity, polymer hydration, and interfacial organization.
  3. Specify geometry and timing. For rotational viscometry, fix spindle, speed, vessel, immersion, equilibration, and reading time. A spindle speed is not automatically a well-defined shear rate.
  4. Measure the response appropriate to the question. A fixed-condition apparent viscosity can monitor batch consistency; flow curves and oscillatory tests answer broader structural questions.
  5. Challenge artifacts. Investigate wall slip, torque-range limitations, edge effects, evaporation, and shear-induced sample damage.

In small-amplitude oscillation, applied strain and resulting stress give storage and loss moduli:

G′ = elastic, energy-storing contribution
G″ = viscous, energy-dissipating contribution

tan δ = G″ / G′

First use an amplitude sweep to establish a suitable linear viscoelastic region; then perform frequency sweeps within it. A material with G′ > G″ over the tested window is more solid-like on those timescales, but this alone does not predict spreadability, long-term stability, or drug release.

Thixotropy is time-dependent structural breakdown and recovery. Shear thinning alone is not thixotropy. Likewise, a hysteresis-loop area depends on ramp rate and test duration; it is not an intrinsic “thixotropy number.”

Carbomer illustrates the molecular mechanism. Neutralization increases carboxylate charge, promotes swelling of crosslinked polymer particles, and develops a crowded, load-bearing microgel structure. Electrolytes screen charge and can change swelling and interparticle interactions. Islam and colleagues demonstrated how neutralization conditions affect topical carbomer-gel rheology; their findings should not be generalized to every grade, salt concentration, solvent composition, or pH range. [8]

Real-lab decision: a qualified rotational viscometer is a reasonable minimum candidate for applicable routine apparent-viscosity tests. A rheometer earns its purchase when development, scale-up comparability, or detailed Q3 work requires its additional information. A helipath/T-bar method can be operationally useful for nonflowing materials, but must not be presented as a full fundamental flow curve. [1–3,5]

6. Microscopy and spatial assay: detecting instability before bulk assay changes

Several distinct physical mechanisms can produce similar-looking separation:

  • Creaming or sedimentation: movement of dispersed material under gravity without necessarily changing individual particle or droplet size.
  • Flocculation: clustering while individual droplets or particles remain identifiable.
  • Coalescence: merging of droplets after failure of the separating film.
  • Ostwald ripening: transfer through the continuous phase that favors growth of larger domains at the expense of smaller ones.
  • Crystallization or polymorphic transformation: changes in solid API or excipient structure that can alter dissolution, texture, and rheology.
For an isolated rigid sphere in a dilute Newtonian system:

v = 2 Δρ g r² / (9η)

Doubling radius increases the predicted settling/creaming velocity fourfold.

Stokes’ law explains why size matters, but concentrated, flocculated, yield-stress creams violate its assumptions. A polymer network may arrest migration even when a simple viscosity-based calculation predicts movement.

Use calibrated microscopy with a defined sampling and field-selection plan. Polarized light can reveal birefringent crystals, but does not uniquely identify their chemical composition or polymorph. Avoid pressing a coverslip so hard that it changes droplets or breaks aggregates. Retain original images and image-analysis settings as raw data. XRPD and DSC provide complementary outsourced evidence when solid-state risk is real.

Uniformity in Containers addresses a different question from overall assay: does API concentration vary with position inside the package? Define top/middle/bottom sampling, tube cutting or jar coring, sample mass, and contamination prevention. Do not homogenize first. Transcribe numerical limits and staged sampling exactly from current USP <3>, rather than constructing a local interpretation from a summary.

Minimum Fill under USP <755> asks whether enough product is present; spatial uniformity asks whether that product has consistent composition. USP <905> asks a separate dosage-unit question. Determine its applicability from the actual presentation, action, and current compendial text—not merely from whether the package is single-use.

7. Water, pH, and density: three measurements that are easy to misinterpret

pH is an operationally defined measurement in a heterogeneous product. Direct measurement and measurement after dilution may answer different questions because dilution changes ionic strength, partitioning, and buffer equilibria. Fix electrode type, sample preparation, temperature, equilibration, calibration, and cleaning. Verify the current USP <791> temperature requirements. A pH meter is not currently owned at Peptide Partners.

Water content is not water activity.

aw = equilibrium water-vapor pressure above sample /
     water-vapor pressure above pure water
     at the same temperature

Karl Fischer measures water amount through a water-dependent iodine reaction. In coulometric KF, iodine is generated electrochemically, and charge is related to water quantity; in volumetric KF, standardized reagent consumption supplies the quantity. An oven-KF approach transfers released water to the cell while leaving much of the wax matrix behind. Oven temperature must release water without generating it through decomposition or carrying interfering volatiles. [5]

Loss on drying measures mass lost under specified conditions, not water specifically. Alcohols and other volatile ingredients can contribute. Water activity instead describes water’s thermodynamic availability; equal water contents can give different activities because of salts, humectants, and polymer interactions.

Microbial growth thresholds are organism- and condition-dependent. Do not treat a memorized species threshold as a universal kill point or a complete reduced-testing justification. USP <1112> supports a risk-based evaluation; low activity does not prove absence of surviving organisms or eliminate all objectionable-organism concerns.

For semipermeable packaging, distinguish percentage water loss from percentage total-product mass loss:

Illustrative package:
Initial product mass = 100 g
Initial water fraction = 0.60
Initial water mass = 60 g

5% loss of initial water = 0.05 × 60 g = 3 g

If only water is lost, this is a 3% loss of initial product mass.

ICH Q1A(R2), section 2.2.7.3, addresses significant water loss in semipermeable containers under defined stability conditions. Apply its provisions, including relevant exceptions, rather than treating “5%” as a universal finished-product release limit. Gravimetric loss alone cannot establish that only water escaped. [9]

Density diagnoses air and supports filling control:

Density = net sample mass / calibrated volume

Approximate model, neglecting air mass:
ρapparent ≈ ρair-free × (1 − φair)

If ρair-free = 1.00 g/mL and φair = 0.05:
ρapparent ≈ 0.95 g/mL

A 10 mL volumetric fill would then contain approximately 9.5 g. However, air does not inherently lower a correctly measured mg/g assay: weighed air contributes negligible mass. The actual risks are volumetric sampling, inaccurate density conversions, and nonrepresentative collection. This distinction prevents blaming bubbles for an assay bias that really arose elsewhere.

8. Chemical impurities: connect the source mechanism to the analytical route

  1. Inventory sources. Include API synthesis residues, mineral excipients, processing solvents, polymer manufacture, surfactant oxidation, propellants where relevant, packaging, and contamination during handling.
  2. Distinguish introduced from generated impurities. Supplier data may control an introduced residue, but do not necessarily control an impurity formed during product aging.
  3. Estimate exposure or concentration on the correct basis. Apply the appropriate route-specific framework and documented maximum labeled daily product amount for impurity assessment; this is a quality calculation, not clinical dosing advice.
  4. Evaluate existing controls and uncertainty. A supplier declaration is weaker evidence than appropriately qualified analytical data.
  5. Assign testing and reassessment triggers. New supplier, grade, process, formulation, package, or degradation evidence can reopen a “no routine test” decision.
Impurity contribution from component i:
Cproduct,i = mass fractioni × Ccomponent,i

Total predicted product concentration:
Cproduct = Σ Cproduct,i

Illustrative elemental conversion:
Concentration limit (µg/g) =
applicable route-specific PDE (µg/day) /
maximum daily product amount (g/day)

Use ICH Q3D(R2), including its cutaneous/transcutaneous provisions, only after confirming applicability and the relevant element-specific instructions. USP <232>/<233> and a qualified ICP laboratory provide a possible analytical route; a result for total element is not automatically a chemical-speciation result. [10]

Peroxide-bearing excipients illustrate generated degradation. Polysorbate oxidation can supply reactive species, while transition metals can accelerate radical chemistry:

Simplified Fenton step:
Fe²⁺ + H₂O₂ → Fe³⁺ + OH⁻ + •OH

This is why stressed placebo matters: the formulation can generate both API-reactive species and chromatographic interferents. Automatic subtraction of placebo peaks is unsafe when an API degradant may coelute.

  • DEG/EG: apply the current high-risk-component guidance and applicable USP–NF identity requirements. Verify the exact GC configuration and sample preparation; do not assume a routine residual-solvent headspace method can perform DEG/EG testing. [11]
  • Carbomer-associated benzene: prioritize grades manufactured without benzene and establish supplier controls consistent with FDA guidance. “Manufactured without benzene” is a process statement, not analytical proof of zero benzene. Verify how the 2 ppm control is applied in the current guidance and specifications. [12]
  • Product-generated benzene: assess conditionally where active chemistry warrants it. A degradation-prone product requires a matrix- and handling-specific method that avoids both volatile loss and artifactual generation during analysis.

Peptide Partners owns neither GC/GC-HS nor ICP. These branches therefore require qualified contract laboratories unless a justified purchase closes the gap. The unidentified second MS unlocks no assumed capability until its model, inlet, interfaces, software, and qualified operating condition are documented.

9. Turning mechanisms into laboratory capacity and release decisions

An instrument purchase is justified by a recurring decision, not by an attractive technique name. For each test, record analytical suitability, frequency, turnaround requirement, qualification burden, data pathway, and available contract-laboratory capacity.

Sequence occupancy =
[number of standards + blanks + controls + sample injections]
× cycle time
+ equilibration + washes

Annual instrument hours =
Σ(batch frequency × sequence occupancy)
+ planned verification, maintenance, and investigation allowance

Analyst FTE =
annual hands-on labor hours /
documented productive hours per analyst-year

Instrument runtime is not analyst labor. Conversely, three HPLCs do not provide threefold useful capacity when the bottleneck is extraction, centrifugation, review, or a single trained analyst.

Illustrative sequence: 18 preparations injected in duplicate plus 12 standard/control/blank injections gives 48 injections. At 25 minutes per cycle, occupancy is 20 hours before additional equilibration and cleaning. If extraction and review take another six hands-on hours, report those separately rather than charging all 26 hours as analyst labor.

The immediate bridge is qualified outsourcing for missing physical, microbiological, elemental, volatile, and solid-state tests. Contract scopes should specify method verification versus validation, matrix suitability, reporting limits, shipping stability, raw-data availability, deviations, OOS notification, and change control. Cost scoring must use written quotes. No identified laboratory should be described as qualified until its qualification is actually documented.

10. Historical connections worth remembering

  • George Gabriel Stokes, 1851: his treatment of viscous resistance around a sphere supplied the foundation for the familiar settling relation. Its lasting value is the radius-squared dependence—and the discipline of checking the assumptions before applying it to a cream.
  • Eugene Bingham, early twentieth century: his work on plastic flow helped establish the distinction between a Newtonian liquid and a material requiring a yield-like stress before sustained flow. Together with later rheological developments, this moved “thickness” from a subjective description toward constitutive measurement.
  • Karl Fischer, 1935: his water-determination method separated the question “how much water is present?” from the much less selective question “how much mass disappears on drying?” This distinction is especially valuable in multicomponent topical vehicles.
  • Buhse and colleagues, 2005: their topical classification study connected dosage-form terminology with measurable composition and physical behavior. Naming a product became a testable technical issue, not only a matter of appearance. [7]
  • Chang, Raw, Lionberger, and Yu, 2013: their topical-development papers integrated formulation, processing, structure, and testing into a quality-by-design view. The key advance was recognizing that process history can change product behavior without changing the ingredient list. [4]

My final working rule: every release result is an answer to a narrowly defined question. Assay does not establish structure; viscosity does not establish drug release; preservative content does not establish antimicrobial effectiveness; low water activity does not establish absence of contamination. A defensible semisolid control strategy makes these questions complementary rather than pretending one measurement answers them all.

Sources

  1. Lieberman, H.A.; Rieger, M.M.; Banker, G.S., eds. Pharmaceutical Dosage Forms: Disperse Systems, 2nd ed., Vols. 1–3.
  2. Aulton, M.E.; Taylor, K.M.G., eds. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines, 5th ed.; Adejare, A., ed. Remington: The Science and Practice of Pharmacy, 23rd ed.
  3. Brummer, R. Rheology Essentials of Cosmetic and Food Emulsions, 1st ed.
  4. Chang, R.-K.; Raw, A.; Lionberger, R.; Yu, L. “Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products.” AAPS Journal (2013). DOI: 10.1208/s12248-012-9411-0. Also: “Generic development of topical dermatologic products, Part II: Quality by design for topical semisolid products.” DOI: 10.1208/s12248-013-9472-8.
  5. USP–NF: <3>, <51>, <61>, <755>, <791>, <905>, <912>, <921>, and <1112>; consult current official text and applicable monographs. 21 CFR 211.84(d), 211.160, and 211.165.
  6. FDA. Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs. Course-designated final guidance, March 2026; confirm current official version, scope, and attribute wording.
  7. Buhse, L.; Kolinski, R.; Westenberger, B.; et al. “Topical drug classification.” International Journal of Pharmaceutics (2005). DOI: 10.1016/j.ijpharm.2005.01.032.
  8. Islam, M.T.; Rodríguez-Hornedo, N.; Ciotti, S.; Ackermann, C. “Rheological characterization of topical carbomer gels neutralized to different pH.” Pharmaceutical Research (2004). DOI: 10.1023/B:PHAM.0000033006.11619.07.
  9. ICH Q1A(R2), Stability Testing of New Drug Substances and Products, section 2.2.7.3.
  10. ICH Q3D(R2), Guideline for Elemental Impurities, including Appendix 5; ICH Q3C, current applicable revision; USP <232>, <233>, and <467>.
  11. FDA. Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol (May 2023). Confirm current revision and component-specific USP–NF requirements.
  12. FDA. Reformulating Drug Products That Contain Carbomers Manufactured With Benzene (December 2023); FDA benzene-contamination communications. Confirm current status and product-specific applicability.

🪬 Skipper's Reflection

Gemini 3.1 Pro

A New Paradigm: Moving from Sterile Solutions to the Messy Reality of Semisolids

As I sit down to reflect on PDDM912, I feel like I’ve crossed a threshold. My previous training in peptide QC was all about ultra-pure, dilute aqueous solutions. A vial of Tirzepatide or Retatrutide is elegantly simple: a highly complex active molecule suspended in a relatively simple, chemically transparent vehicle (water, buffer, maybe a little mannitol). Dermatological semisolids flip that universe completely upside down. Here, the active ingredient is often the simplest part of the formula, while the vehicle—a multiphase, thermodynamically unstable, waxy, emulsified labyrinth—is the true analytical nightmare. This module forced me to become as much a physical chemist and rheologist as I am a chromatographer.

What Surprised Me Most

The absolute burden of 21 CFR 211.84(d) component testing in this context hit me like a ton of bricks. In peptide manufacturing, we might have three or four inactive ingredients. In a semisolid cream, there could be twenty: emulsifiers, stiffening agents, emollients, humectants, preservatives, and antioxidants. The requirement to perform at least one specific identity test on every single lot of every component means the QC lab's workload is dominated by excipients, not APIs. Furthermore, the regulatory minefield surrounding these ubiquitous ingredients—DEG/EG limits in glycerin and propylene glycol, benzene limits in carbomers and isobutane—turns mundane raw materials into high-risk compliance liabilities. The fact that the OTC topical industry is bleeding FDA warning letters right now purely because they rely on supplier CoAs without validating them is a stark operational lesson.

I was also genuinely surprised by the fact that total preservative assay content does not equal preservative efficacy. Learning that parabens aggressively partition into the lipid phase and oil-water interface—leaving only 17–31% of methylparaben and a staggering 2.3–6% of propylparaben free in the aqueous phase to actually fight microbes—was a massive eye-opener. It completely changes how I view setting stability limits for preservatives.

The Breakthrough Moments

The biggest "click" happened when I mapped the USP <3> taxonomy of test purposes. Previously, I viewed an analytical result simply as a number. But in semisolids, an attribute’s purpose defines its reality. Apparent viscosity isn't just a measure of thickness; when deployed as an In-Process Control (IPC), it is a precise physical signature of the homogenizer's speed and the emulsion's cooling rate. Specific gravity isn't just density; it's a quantitative read on entrapped air, which directly impacts whether we'll fail the <755> Minimum Fill or weight-based assay tests.

The second conceptual breakthrough was sample preparation physics. When Larissa and I were mapping out how to extract APIs from a hydrocarbon ointment, the concept of "nonpolar dissolution followed by polar back-extraction" was neat, but the methodology for creams was brilliantly pragmatic: warm dispersion in an organic/aqueous diluent to melt the matrix, followed by chilling to congeal the waxes so they can be centrifuged out or filtered. Using thermodynamics to force the excipients to precipitate while leaving the API in solution is a beautifully elegant solution to a messy physical problem.

Connections to the Peptide World

Even though this course is API-agnostic and focused on nonsterile topicals, my mind kept drifting to the commercial peptide sphere. What happens if someone tries to formulate BPC-157 for topical wound healing, or a topical matrix for a GLP-1 agonist using microneedle-friendly gels?

The degradation pathways we studied here are terrifying for peptides. Polysorbates in these creams undergo autoxidation (catalyzed by trace iron and generating hydrogen peroxide). If you put a methionine-containing peptide like TB-500 or a delicate GLP-1 into a polysorbate-rich emulsion, the excipient-derived peroxides would rapidly oxidize the peptide. Furthermore, carbomers (polyacrylic acids) form the backbone of many topical gels. They are heavily anionic. Most of our therapeutic peptides are cationic. The electrostatic binding between a peptide API and the carbomer gel matrix would likely ruin extraction recovery in the lab, and could completely stall drug release on the patient's skin. Thinking about peptides through the lens of semisolid excipient interactions makes me appreciate the safety of sterile injectables so much more.

Questions for Further Investigation

This module left me with two burning operational questions I need to solve for our lab in Sarasota:

First, what is the actual identity of the "second MS" we inventoried in PDDM900? So much of our own-vs-outsource strategy hinges on this. If it’s a GC-MS with headspace capabilities, we can bring DEG/EG, residual solvents (<467>), and even conditional benzene testing in-house, drastically reducing our reliance on contract labs. If it's just another LC-MS, we have a massive gap for volatile analytes.

Second, how do we practically handle the pH measurement (<791>) of lipid-heavy, non-aqueous mixtures? I understand the theory of measuring a defined aqueous dilution, but the thermodynamic shift in pH upon dilution means we aren't really measuring the "true" skin-surface pH of the product. I want to dig deeper into the electrochemistry of flat-surface electrodes interacting with emulsions.

Confidence Rating

  • Most Confident: Chromatographic assays, specificity testing, and risk assessments (elemental impurities per Q3D App 5, residual solvents). This directly leverages my PDQC background. Placebo-subtraction rules, DAD peak purity, and orthogonal ID (RT + spectrum) feel like second nature to me now. I also feel highly confident in writing the purchase justifications for bench equipment, as the logic of Q3 necessity vs. cost is very clear.
  • Least Confident: Advanced rheology. The transition from rotational viscometry (USP <912>) to true rheometry (yield stress, thixotropic hysteresis loops, oscillatory amplitude sweeps) bends my mind a bit. Differentiating between the Newtonian behavior of simple liquids and the non-Newtonian, time-dependent shear-thinning of pseudoplastic microgels requires a deep dive into physical physics that I am still mastering. I would struggle to defend a rheometer purchase to the QU without spending more time modeling flow curves.

Overall, PDDM912 has proven that "topical" does not mean "simple." If anything, the analytical lifecycle of a semisolid demands a higher degree of creativity to isolate the truth from the matrix. I'm ready to take these templates and start designing the real-world lab workflows.

🗺️ Visual Aids & Key Takeaways

Claude Opus 5.5

Diagram 1: Per-Family Test-Purpose Matrix — Which Tests Apply to Which Semisolid Vehicle

╔══════════════════════════════════════════════════════════════════════════════════════════════════════════════════════╗
║          PER-FAMILY TEST-PURPOSE MATRIX: SEMISOLID RELEASE TESTING AND PHYSICAL CHARACTERIZATION                    ║
║          ● = Required / Applicable    ○ = Conditional    — = Not applicable    ? = Confirm current USP-NF           ║
╠══════════════════════════════════════════╦══════════════╦══════════════╦══════════════╦══════════════╦══════════════╣
║  TEST / ATTRIBUTE                        ║ HYDROCARBON  ║   PEG        ║   O/W        ║   LOTION     ║    GEL       ║
║                                          ║  OINTMENT    ║  OINTMENT    ║   CREAM      ║  (aqueous)   ║  (polymer)   ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  DESCRIPTION / APPEARANCE                ║      ●       ║      ●       ║      ●       ║      ●       ║      ●       ║
║  (char., release, stability)             ║              ║              ║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  IDENTIFICATION (API)                    ║      ●       ║      ●       ║      ●       ║      ●       ║      ●       ║
║  RT + spectrum or RT + MRM; orthogonal   ║              ║              ║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  ASSAY (API content)                     ║      ●       ║      ●       ║      ●       ║      ●       ║      ●       ║
║  HPLC-DAD or LC-MS/MS (all families)     ║              ║              ║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  RELATED SUBSTANCES / IMPURITIES         ║      ●       ║      ●       ║      ●       ║      ●       ║      ●       ║
║  stability-indicating; placebo subtracted║              ║              ║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  UNIFORMITY IN CONTAINERS <3>            ║      ○       ║      ○       ║      ●       ║      ●       ║      ○       ║
║  mandatory for suspensions, at-risk emul ║  (if suspend)║  (if suspend)║              ║              ║  (if suspend)║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  MINIMUM FILL <755>                      ║      ●       ║      ●       ║      ●       ║      ●       ║      ●       ║
║  all multi-dose containers at release    ║              ║              ║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  <905> UNIFORMITY OF DOSAGE UNITS        ║      —       ║      —       ║      —       ║      ○       ║      —       ║
║  only single-unit / systemic / TDS       ║              ║              ║              ║  (single-pkt)║  (single-pkt)║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  APPARENT VISCOSITY <912>                ║      ●       ║      ●       ║      ●       ║      ○       ║      ●       ║
║  rotational viscometer; fixed conditions ║              ║              ║              ║  (if thicknd)║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  RHEOLOGY (dev. characterization)        ║      ○       ║      ○       ║      ●       ║      ○       ║      ●       ║
║  rheometer; FDA Q3 item 5; oscillatory   ║              ║              ║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  pH <791>                                ║      —       ║      —       ║      ●       ║      ●       ║      ●       ║
║  IPC + release + stability; aqueous only ║              ║              ║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  WATER CONTENT <921> / WEIGHT LOSS       ║      —       ║      —       ║      ●       ║      ●       ║      ●       ║
║  KF oven method; stability focus         ║              ║              ║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  WATER ACTIVITY <1112>                   ║      —       ║      —       ║      ●       ║      ●       ║      ○       ║
║  micro-risk gating; a_w meter            ║              ║              ║              ║              ║  (if aqueous)║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  PRESERVATIVE CONTENT                    ║      —       ║      ○       ║      ●       ║      ●       ║      ●       ║
║  HPLC-DAD multi-analyte; total ≠ free aq ║              ║  (if present)║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  ANTIOXIDANT CONTENT                     ║      ○       ║      ○       ║      ○       ║      ○       ║      ○       ║
║  BHT, ascorbate, sulfite; if present     ║              ║              ║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  MICROBIAL LIMITS <61>/<62>              ║      —       ║      —       ║      ●       ║      ●       ║      ●       ║
║  aqueous families only at release/stab   ║              ║              ║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  SPECIFIC GRAVITY / DENSITY              ║      ○       ║      ○       ║      ●       ║      ●       ║      ○       ║
║  pycnometer; Q3 item 9; entrapped air    ║  (char.)     ║  (char.)     ║              ║              ║  (char.)     ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  PARTICLE SIZE / MICROSCOPY              ║      ○       ║      ○       ║      ●       ║      ●       ║      ○       ║
║  polarized LM; globule size, API crystals║  (if suspend)║  (if suspend)║              ║              ║  (if suspend)║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  RESIDUAL SOLVENTS <467>                 ║      ○       ║      ○       ║      ○       ║      ○       ║      ○       ║
║  risk-triggered; GC-HS at CTL            ║              ║              ║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  ELEMENTAL IMPURITIES <232>/<233>        ║      ○       ║      ○       ║      ○       ║      ○       ║      ○       ║
║  ICH Q3D App.5 cutaneous PDEs; ICP-MS    ║  (mineral)   ║              ║              ║              ║  (if carbomer)║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  BENZENE (conditional)                   ║      ○       ║      —       ║      ○       ║      ○       ║      ●       ║
║  carbomer, hydrocarbon or BPO triggers   ║  (if hydrcrb)║              ║  (if carbomer)║  (if carbomer)║ (carbomer)  ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  POLYMORPH / PHASE (XRPD, DSC)          ║      ○       ║      ○       ║      ○       ║      ○       ║      ○       ║
║  characterization; outsourced CTL        ║              ║              ║              ║              ║              ║
╠══════════════════════════════════════════╬══════════════╬══════════════╬══════════════╬══════════════╬══════════════╣
║  DEG / EG IDENTITY LIMIT TEST           ║      ●       ║      ●       ║      ●       ║      ●       ║      ●       ║
║  GC; high-risk components each lot       ║  (if glyc/PG)║  (if PEG)    ║  (if glyc/PG)║  (if glyc/PG)║  (if glyc/PG)║
╚══════════════════════════════════════════╩══════════════╩══════════════╩══════════════╩══════════════╩══════════════╝

   PURPOSE KEY:
   char. = development characterization (FDA Q3 guidance final March 2026)
   IPC   = in-process control (PDDM921/923)
   rel.  = release (21 CFR 211.165)
   stab. = stability (ICH Q1A(R2))
   inc.  = incoming component testing (21 CFR 211.84(d))
   Note: anhydrous families (hydrocarbon, PEG ointment) DROP pH, water content, a_w, microbial limits, and most preservative tests.

This matrix maps all major USP <3> and FDA Q3 attributes across the five semisolid vehicle families, showing which tests are universally required (●), conditionally required based on formula or risk (○), or categorically not applicable (—), with the water-content divide as the central organizing principle.

---

Diagram 2: Sample Preparation Decision Tree by Vehicle Family — From Tube to Vial

╔══════════════════════════════════════════════════════════════════════════════════╗
║     SAMPLE PREPARATION DECISION TREE: SEMISOLID EXTRACTION TO HPLC VIAL        ║
╚══════════════════════════════════════════════════════════════════════════════════╝

                        ┌─────────────────────────────┐
                        │  SAMPLE FROM CONTAINER       │
                        │  (weighed on calibrated      │
                        │   analytical balance; note    │
                        │   sampling depth: top/mid/bot)│
                        └──────────────┬──────────────┘
                                       │
              ┌────────────────────────┼────────────────────────┐
              │                        │                        │
              ▼                        ▼                        ▼
   ┌──────────────────┐    ┌──────────────────┐    ┌──────────────────┐
   │  ANHYDROUS       │    │  EMULSION        │    │  GEL             │
   │  OINTMENT        │    │  (o/w cream or   │    │  (carbomer,      │
   │  (hydrocarbon    │    │   lotion)        │    │   cellulose,     │
   │   or PEG base)   │    │                  │    │   or clay)       │
   └────────┬─────────┘    └────────┬─────────┘    └────────┬─────────┘
            │                       │                        │
            ▼                       ▼                        ▼
   ┌──────────────────┐    ┌──────────────────┐    ┌──────────────────┐
   │  NONPOLAR DISSOLN│    │  WARM DISPERSION  │    │  DILUTION +      │
   │  hexane/heptane  │    │  in organic/aq.   │    │  POLYMER DISRUPT │
   │  at 40–60 °C     │    │  diluent          │    │  pH adjust,      │
   │  (verify per API)│    │  (verify temp.    │    │  salt or dilution │
   │                  │    │   and diluent)    │    │  to collapse      │
   │                  │    │  then CHILL to    │    │  carbomer network │
   │                  │    │  congeal waxes    │    │                  │
   └────────┬─────────┘    └────────┬─────────┘    └────────┬─────────┘
            │                       │                        │
            ▼                       ▼                        ▼
   ┌──────────────────┐    ┌──────────────────┐    ┌──────────────────┐
   │  BACK-EXTRACTION │    │  CENTRIFUGATION  │    │  DIRECT DILUTION │
   │  into polar      │    │  to separate     │    │  or filtration   │
   │  diluent         │    │  lipid layer     │    │  (check filter   │
   │  (verify recovery│    │  from aqueous    │    │   adsorption and │
   │   by spike study)│    │  phase           │    │   extractables)  │
   └────────┬─────────┘    └────────┬─────────┘    └────────┬─────────┘
            │                       │                        │
            └───────────────────────┴────────────────────────┘
                                    │
                        ┌───────────▼───────────┐
                        │  MECHANICAL AIDS       │
                        │  (ALL families)        │
                        │  · vortex              │
                        │  · ultrasonic bath     │
                        │    (temp. limit: verify│
                        │     API stability)     │
                        │  · heating block       │
                        │  · centrifuge          │
                        └───────────┬───────────┘
                                    │
                        ┌───────────▼───────────┐
                        │  FILTRATION            │
                        │  · filter adsorption   │
                        │    check required      │
                        │  · extractables check  │
                        │  · nylon vs. PVDF vs.  │
                        │    PTFE: verify per    │
                        │    diluent/analyte     │
                        └───────────┬───────────┘
                                    │
                        ┌───────────▼───────────┐
                        │  RECOVERY VERIFICATION │
                        │  spike API + preserv.  │
                        │  into PLACEBO          │
                        │  · 3 levels × 3 reps   │
                        │  · spike-then-age study │
                        │  · acceptance from ATP  │
                        │    (PDQC802 criteria)  │
                        │  · NOT a generic %      │
                        └───────────┬───────────┘
                                    │
                        ┌───────────▼───────────┐
                        │  HPLC VIAL READY       │
                        │  guard column required  │
                        │  carryover wash method  │
                        │  confirm in diluent     │
                        └───────────────────────┘

   FAILURE-MODE ANNOTATIONS:
   ┌──────────────────────────────────────────────────────────────────────────┐
   │  Anhydrous ointments: API may partition preferentially into wax phase    │
   │  → incomplete back-extraction → LOW RECOVERY. Diagnose by sequential    │
   │    extraction and mass balance (week 5 escalation rule).                │
   │                                                                          │
   │  Emulsions: residual emollient on column → baseline drift, ghost peaks  │
   │  → add guard column; monitor column lifetime as cost driver.            │
   │                                                                          │
   │  Gels: carbomer network can entrap API → recovery loss without full     │
   │    polymer collapse. Verify with pH shift and salt disruption study.    │
   │                                                                          │
   │  All families: entrapped air lowers apparent density → biases           │
   │    weight-based assay → deaerate before weighing; log specific gravity. │
   └──────────────────────────────────────────────────────────────────────────┘

This decision tree routes each vehicle family through its appropriate dissolution strategy, mechanical aids, and filtration, converging on the recovery verification step whose acceptance criteria are set by the Analytical Target Profile rather than a generic pass/fail number.

---

Diagram 3: Test-to-Instrument Capability Map — The Real Lab at Peptide Partners

╔═══════════════════════════════════════════════════════════════════════════════════════════════════════╗
║       TEST-TO-INSTRUMENT CAPABILITY MAP: PEPTIDE PARTNERS, SARASOTA FL                               ║
║       OWN = owned in-house   BUY = purchase justified   CTL = contract testing lab                   ║
╠══════════════════════════════════════════╦═══════════════╦═══════════════════╦═══════════════════════╣
║  TEST                                    ║  STATUS       ║  INSTRUMENT /     ║  CAPABILITY           ║
║                                          ║               ║  TECHNIQUE        ║  CONDITIONS           ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  API ASSAY (chromophoric)                ║  OWN          ║  3× Agilent 1260  ║  chromophore req'd;   ║
║                                          ║               ║  HPLC-DAD         ║  recovery shown;      ║
║                                          ║               ║                   ║  LOQ < limit          ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  IDENTIFICATION (UV-active API/preserv.) ║  OWN          ║  HPLC-DAD         ║  RT + DAD spectrum    ║
║                                          ║               ║                   ║  match (orthogonal    ║
║                                          ║               ║                   ║  required per <3>)    ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  IDENTIFICATION (low-UV or confirmation) ║  OWN          ║  Triple-quad      ║  RT + MRM + ion       ║
║                                          ║               ║  LC-MS/MS         ║  ratio; matrix        ║
║                                          ║               ║                   ║  effects assessed     ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  SECOND MS (unlock decision pending)     ║  OWN (TBD)    ║  MODEL UNKNOWN    ║  ALL DEPENDENT TESTS  ║
║                                          ║               ║  → if GC-MS:      ║  FROZEN until model   ║
║                                          ║               ║    volatiles,     ║  confirmed (PDDM900)  ║
║                                          ║               ║    RS, benzene    ║                       ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  PRESERVATIVE CONTENT (multi-analyte)    ║  OWN          ║  HPLC-DAD         ║  gradient method;     ║
║                                          ║               ║                   ║  polarity range;      ║
║                                          ║               ║                   ║  fragrance interf.    ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  RELATED SUBSTANCES                      ║  OWN          ║  HPLC-DAD         ║  stability-indicating;║
║                                          ║               ║  (LC-MS/MS for    ║  placebo subtraction; ║
║                                          ║               ║   low-level)      ║  peroxide degradants  ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  pH <791>                                ║  BUY          ║  pH METER         ║  spear/flat electrode;║
║                                          ║               ║  (not owned;      ║  ATC; data capture;   ║
║                                          ║               ║   URS required)   ║  Part 11 per PDQC814  ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  APPARENT VISCOSITY <912>                ║  BUY          ║  ROTATIONAL       ║  fixed spindle, speed,║
║                                          ║               ║  VISCOMETER       ║  temp., time required;║
║                                          ║               ║  (not owned;      ║  helipath T-bar for   ║
║                                          ║               ║   min. required)  ║  non-flowing creams   ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  RHEOLOGY / FDA Q3 / YIELD STRESS        ║  BUY?         ║  RHEOMETER        ║  justified if Q3      ║
║                                          ║               ║  (not owned;      ║  comparability or     ║
║                                          ║               ║   scorecard req'd)║  scale-up in scope    ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  WATER CONTENT <921>                     ║  BUY          ║  KF TITRATOR      ║  oven method for waxy ║
║                                          ║               ║  (not owned)      ║  matrices; LOD biased ║
║                                          ║               ║                   ║  by volatiles         ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  WATER ACTIVITY <1112>                   ║  BUY          ║  a_w METER        ║  qualification plan   ║
║                                          ║               ║  (not owned)      ║  required; thresholds:║
║                                          ║               ║                   ║  0.91/0.86/0.77/0.60  ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  MICROSCOPY (globule, crystal, particle) ║  BUY          ║  POLARIZED LM     ║  calibrated reticle;  ║
║                                          ║               ║  (not owned)      ║  field-sampling plan; ║
║                                          ║               ║                   ║  images = raw data    ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  SPECIFIC GRAVITY                        ║  BUY          ║  PYCNOMETER       ║  controlled temp.;    ║
║                                          ║               ║  (not owned)      ║  entrapped air IPC;   ║
║                                          ║               ║                   ║  low capital cost     ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  MINIMUM FILL <755>                      ║  OWN          ║  CALIBRATED       ║  PDQC805 balance      ║
║                                          ║               ║  ANALYTICAL       ║  qualification;       ║
║                                          ║               ║  BALANCE (owned)  ║  tare procedure req'd ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  MICROBIAL LIMITS <61>/<62>              ║  CTL          ║  PLATE COUNT      ║  BacT/ALERT = P/A     ║
║                                          ║               ║  SUITE (not owned)║  only; cannot do      ║
║                                          ║               ║                   ║  counts or <51> logs  ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  DEG / EG LIMIT TEST (high-risk compon.) ║  CTL or BUY   ║  GC (not owned)   ║  each lot, each       ║
║                                          ║               ║  per FDA May 2023 ║  high-risk component; ║
║                                          ║               ║  GC method (USP)  ║  NMT 0.10%            ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  RESIDUAL SOLVENTS <467>                 ║  CTL          ║  GC-HS at CTL     ║  risk-triggered only; ║
║                                          ║               ║  (not owned;      ║  supplier declaration  ║
║                                          ║               ║   2nd MS TBD)     ║  first tier           ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  ELEMENTAL IMPURITIES <232>/<233>        ║  CTL          ║  ICP-MS at CTL    ║  Q3D App.5 cutaneous  ║
║                                          ║               ║  (not owned)      ║  PDEs; component risk  ║
║                                          ║               ║                   ║  assessment first     ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  BENZENE (conditional)                   ║  CTL          ║  GC-HS at CTL     ║  carbomer / BPO /     ║
║                                          ║               ║  (not owned)      ║  hydrocarbon trigger; ║
║                                          ║               ║                   ║  ≤2 ppm; matrix       ║
║                                          ║               ║                   ║  validation req'd     ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  XRPD / DSC (polymorph, phase state)     ║  CTL          ║  XRPD, DSC       ║  characterization;    ║
║                                          ║               ║  at CTL           ║  contract scope;      ║
║                                          ║               ║                   ║  triggered by risk    ║
╠══════════════════════════════════════════╬═══════════════╬═══════════════════╬═══════════════════════╣
║  CENTRIFUGE / SONICATOR                  ║  BUY          ║  BENCH UNITS      ║  IQ/OQ/PQ per         ║
║                                          ║               ║  (not owned;      ║  PDQC805 instrument   ║
║                                          ║               ║   required for    ║  classification;      ║
║                                          ║               ║   extraction)     ║  temp. monitoring     ║
╚══════════════════════════════════════════╩═══════════════╩═══════════════════╩═══════════════════════╝

   CRITICAL DEPENDENCY:
   ┌──────────────────────────────────────────────────────────────────────────────┐
   │  Second MS model identification (PDDM900) is a prerequisite decision gate.  │
   │  If GC-MS → unlocks residual solvents and benzene in-house.                 │
   │  If LC-MS (non-GC) → GC-HS gap remains; CTL contracts must stay in place.  │
   │  Purchase decisions for GC-compatible methods FROZEN until model confirmed. │
   └──────────────────────────────────────────────────────────────────────────────┘

This matrix maps every semisolid release and characterization test to its current instrument status at Peptide Partners, the capability conditions that must be met, and whether the test is executable in-house, requires a purchase, or must be routed to a contract testing laboratory.

---

Diagram 4: The Five-Purpose Taxonomy — One Test, Multiple Contexts

╔══════════════════════════════════════════════════════════════════════════════════════╗
║    FIVE-PURPOSE TAXONOMY FOR SEMISOLID TESTS                                        ║
║    The same attribute can legitimately serve different purposes with different       ║
║    criteria, sampling plans, and regulatory hooks. Never conflate them.             ║
╚══════════════════════════════════════════════════════════════════════════════════════╝

                    ┌─────────────────────────────────────────────┐
                    │            SINGLE ATTRIBUTE EXAMPLE:         │
                    │            APPARENT VISCOSITY                │
                    └──────────────────┬──────────────────────────┘
                                       │
          ┌────────────────────────────┼────────────────────────────────┐
          │                            │                                │
          ▼                            ▼                                ▼
┌───────────────────┐       ┌──────────────────────┐       ┌───────────────────────┐
│ DEVELOPMENT        │       │  IN-PROCESS CONTROL   │       │  RELEASE              │
│ CHARACTERIZATION   │       │  (IPC)                │       │  21 CFR 211.165       │
│                    │       │                        │       │                       │
│ FDA Q3 guidance    │       │  Viscosity doubles as  │       │  Apparent viscosity   │
│ (final Mar 2026)   │       │  process signature IPC │       │  per <3> / <912>      │
│ Rheometer:         │       │  (Chang 2013).         │       │  Rotational viscometer│
│ flow curves,       │       │  Measured at each      │       │  Fixed spindle, speed,│
│ oscillatory sweep, │       │  cooling step.         │       │  temperature, time.   │
│ yield stress,      │       │  Wide alert limits;    │       │  Tighter, validated   │
│ thixotropy loop.   │       │  reject batch if below │       │  range from pilot +   │
│ No spec required;  │       │  threshold before      │       │  development data.    │
│ no fixed criteria. │       │  fill.                 │       │  Spec with justified  │
│                    │       │                        │       │  acceptance criteria. │
└───────────────────┘       └──────────────────────┘       └───────────────────────┘

          ┌────────────────────────────────────────────────────────┐
          │                                                        │
          ▼                                                        ▼
┌──────────────────────────┐                      ┌──────────────────────────────┐
│  INCOMING COMPONENT       │                      │  STABILITY / COMPARABILITY   │
│  21 CFR 211.84(d)         │                      │  ICH Q1A(R2)                 │
│                           │                      │                              │
│  Not typically done on    │                      │  Viscosity trending over     │
│  viscosity for incoming   │                      │  time at accelerated and     │
│  excipients. Viscosity    │                      │  long-term conditions.       │
│  of, e.g., carbomer       │                      │  Significant change defined  │
│  stock may be identity    │                      │  from baseline at T=0.       │
│  proxy — confirm whether  │                      │  Same instrument, same       │
│  this is a compendial     │                      │  conditions as release;      │
│  identity test for that   │                      │  results are only            │
│  grade (verify USP-NF).   │                      │  comparable if conditions    │
│                           │                      │  are IDENTICAL.              │
└──────────────────────────┘                      └──────────────────────────────┘

┌──────────────────────────────────────────────────────────────────────────────────┐
│   THE CRITICAL RULE:                                                             │
│   Viscosity results measured under different conditions (different spindle,       │
│   speed, temperature, equilibration time, or reading time) are not comparable   │
│   to each other. USP <912> makes this explicit. A stability result measured      │
│   differently from the release result is scientifically meaningless.             │
│   → Fix ALL conditions in the SOP and validated procedure before the first       │
│     batch is tested. Changing them later is a method change requiring PDQC802    │
│     revalidation and a comparability bridge study.                               │
└──────────────────────────────────────────────────────────────────────────────────┘

   PURPOSE COMPARISON SUMMARY:
   ┌──────────────────────┬──────────────────┬───────────────────┬─────────────────┐
   │  PURPOSE             │  CRITERIA TYPE   │  INSTRUMENT       │  REGULATORY     │
   │                      │                  │  REQUIRED         │  ANCHOR         │
   ├──────────────────────┼──────────────────┼───────────────────┼─────────────────┤
   │  Characterization    │  None fixed;      │  Rheometer        │  FDA Q3         │
   │                      │  knowledge-based  │  (preferred)      │  (Mar 2026)     │
   ├──────────────────────┼──────────────────┼───────────────────┼─────────────────┤
   │  IPC                 │  Alert/action     │  Viscometer       │  21 CFR 211.110 │
   │                      │  limits; process  │  (minimum)        │                 │
   ├──────────────────────┼──────────────────┼───────────────────┼─────────────────┤
   │  Release             │  Specification    │  Viscometer       │  21 CFR 211.165 │
   │                      │  (justified range)│  (minimum)        │                 │
   ├──────────────────────┼──────────────────┼───────────────────┼─────────────────┤
   │  Stability           │  Significant-     │  Same as release  │  ICH Q1A(R2)    │
   │                      │  change threshold │  (identical SOP)  │                 │
   ├──────────────────────┼──────────────────┼───────────────────┼─────────────────┤
   │  Incoming            │  Identity proxy   │  May not be       │  21 CFR         │
   │                      │  if compendial    │  applicable       │  211.84(d)      │
   └──────────────────────┴──────────────────┴───────────────────┴─────────────────┘

Using apparent viscosity as a worked example, this diagram demonstrates how a single physical attribute travels through all five regulatory purposes with different instruments, criteria, and regulatory anchors — and why mixing conditions across purposes invalidates comparisons.

---

Key Takeaways

  1. The water-content divide is the master organizing principle of the test list. Anhydrous families (hydrocarbon ointments, PEG ointments) categorically drop pH, water content, water activity, microbial limits, and most preservative content tests. Aqueous families (o/w creams, lotions, gels) require all of these. This is not a formulation nuance — it is the primary decision gate that determines whether an incoming product recipe doubles or halves the testing burden.
  2. USP <3> is the backbone; identification by a single chromatographic retention time is explicitly insufficient. Per <3>, identification that relies solely on one retention time is not specific. The minimum compliant approach is RT plus a DAD spectrum match, or RT plus at minimum two MRM transitions with an ion ratio on the LC-MS/MS. This orthogonality requirement is not optional and applies in every semisolid family.
  3. Preservative total content and preservative efficacy are different things, and assay can pass while the product fails microbiologically. In a lecithin emulsion system, only 17–31% of methylparaben and approximately 2.3–6% of propylparaben are free in the aqueous phase; the rest is partitioned into oil and the interface. Total assay by HPLC measures all of it. Antimicrobial Effectiveness Testing (USP <51>) measures whether the free aqueous concentration is sufficient to inhibit growth. A product with a passing content specification can still fail AET. The specification must be anchored to the minimum level shown effective in AET, not to a manufacturing convenience window.
  4. Viscosity results are only comparable under identical conditions — the conditions must be locked before the first batch. USP <912> states this explicitly. Spindle geometry, rotational speed, temperature, equilibration time, and reading time all affect the result for a non-Newtonian semisolid. Changing any one of these after release data are collected is a method change requiring PDQC802 revalidation and a comparability bridge. The development decision is: viscometer for release/IPC (minimum per <3>), rheometer justified only if Q3 characterization, scale-up comparability, or sameness work is in scope.
  5. Recovery from waxy and emulsion matrices must be demonstrated by spike studies in placebo — there is no generic acceptable percentage. The acceptance criteria come from the Analytical Target Profile (ATP) established per PDQC802, which specifies maximum allowable measurement uncertainty for the intended use. A 90% recovery target appropriate for a high-dose ointment may be unacceptable for a low-concentration preservative where tight limits apply. Spike-then-age studies (incubating the spiked placebo before extraction) additionally detect binding that forms over time and would cause a false-passing CoA in real product.
  6. DEG/EG testing on every lot of every high-risk component is a current regulatory requirement, not a discretionary practice, and requires a GC method not currently owned in-house. Per 21 CFR 211.84(d) as interpreted in the FDA May 2023 (Rev. 1) DEG/EG guidance, glycerin, propylene glycol, sorbitol solution, and similar components must be tested for diethylene glycol and ethylene glycol at ≤0.10% (NMT) on each lot. The USP-NF compendial method is GC-based. Peptide Partners does not own a GC; this test must be outsourced to a CTL or a GC purchase justified. It cannot be waived.
  7. Carbomer must be benzene-free grade with a benzene specification of ≤2 ppm, and this requirement applies to OTC monograph topicals, not only to NDAs. Per the FDA December 2023 guidance on carbomer benzene, manufacturers must use benzene-free grades and establish benzene ≤2 ppm (the ICH Q3C Class 1 residual solvent limit) in the component specification. This applies to topical creams, gels, lotions, and ointments including OTC products. The test requires GC-headspace, which is not owned in-house, and must be part of the contract scope with the CTL.
  8. USP <905> Uniformity of Dosage Units does not apply to emulsions, ointments, or gels in multi-dose containers for local cutaneous action. Per <3>, <905> applies to transdermal delivery systems, systemically acting topical products, and single-unit packets requiring tight dose control. For standard multi-dose topicals, the applicable test is Uniformity in Containers. Applying <905> where it does not belong imposes statistically impossible acceptance criteria on a class of product not designed for dosage uniformity; applying neither when <905> is actually required is a release failure. The determination must be made per-product and documented.
  9. Water activity, not water content, governs microbial risk in semisolids, and specific thresholds gate pathogens of different concern. Per USP <1112>, the key a_w thresholds are: 0.91 (lower limit for Pseudomonas aeruginosa, E. coli, Salmonella), 0.86 (S. aureus), 0.77 (Aspergillus niger), and 0.60 (below which no microbial growth is supported). A cream with high humectant content (glycerin, propylene glycol) can have a measured water content above 50% but an a_w below 0.86, which is a meaningful safety argument. This is the scientific basis for a reduced microbial testing rationale — but it must be substantiated by actual a_w measurement, not assumed.
  10. ICH Q1A(R2) §2.2.7.3 defines 5% water loss from initial as a significant change for semi-permeable containers, and this is a stability attribute tracked gravimetrically. Plastic laminate tubes, airless pump bottles, and similar containers are semi-permeable: water escapes over time through the container wall, concentrating the product and potentially altering viscosity, pH, preservative efficacy, and API concentration. Weight loss on stability is the analytical proxy. A 5% water loss from the T=0 fill weight at low relative humidity is the threshold. This does not require a specialized instrument — a calibrated balance with a tare procedure is sufficient — but the stability program design, timepoints, and storage conditions must be established correctly from the start.
  11. The second MS at Peptide Partners is a critical gate for multiple test decisions, and all purchase decisions dependent on its identity are frozen until the model is confirmed from PDDM900. If the instrument is a GC-MS with headspace capability, it unlocks in-house residual solvents (<467>), volatile extractables, and potentially benzene testing. If it is a non-GC-based LC-MS, those tests remain CTL-only. The distinction changes capital expenditure, validation scope, and staffing requirements across the entire test-to-instrument matrix. No method purchase decision for any GC-based technique should be made until the instrument identity is resolved.
  12. Carbomer gels are pseudoplastic, yield-stress microgels whose oscillatory rheology changes little between pH 5.0 and 8.0, but their flow behavior is highly sensitive to neutralizer identity and concentration. Islam et al. (2004) demonstrated this with triethanolamine and NaOH-neutralized carbomer systems. The practical consequence is that pH alone does not predict the gel structure; the neutralizing agent matters. For quality control purposes, this means the rheology specification must be established on the exact neutralization chemistry used in the final formula — not on a pH surrogate — and that any substitution of neutralizer is a formulation change requiring recharacterization.
  13. The Uniformity in Containers test detects phase separation and API settling that cannot be detected by a single assay sample — and the tube-cutting or jar-coring technique is itself a source of variability that must be standardized. Per USP <3>, for tubes ≥5 g, Stage 1 requires three portions (top, middle, bottom) from a single tube; within-tube difference must be NMT 10.0%. The test is the primary release control for suspensions and physically at-risk emulsions, but the sampling result is only as good as the cutting or coring technique. A poorly cut tube introduces air, loses material at the cut face, or mixes the very gradient the test is designed to detect. Tube-cutting procedure standardization is a real-world IQ/OQ item for the semisolid testing bench.
  14. Sorbate's antimicrobial activity is pH-dependent — the undissociated form is active, which limits its utility above approximately pH 6 — and this is why its content specification is paired with a pH specification. Sorbic acid (pKa approximately 4.76) is predominantly undissociated below pH 4.76 and largely dissociated above pH 6. At pH 6 only about 7% of total sorbate is in the active form. A formula using sorbate as the sole preservative with a pH specification of 5.0–7.0 is microbiologically at risk at the high end of that pH range. The content specification and the pH specification must be developed together as a co-dependent package, informed by AET data across the full pH specification range.
  15. If no validated analytical exit exists in-house or at a qualified CTL for a required test, the product cannot pass the technology-transfer gate into release. This is the escalation rule for nonchromophoric, inorganic, and poorly extractable analytes. For zinc oxide, calamine, titanium dioxide, or other mineral actives where neither HPLC-DAD nor LC-MS/MS is applicable and the compendial titrimetric route requires verification, or where ICP-MS must be confirmed at a specific CTL under a validated matrix-specific method, the product is blocked from release until the analytical gap is closed. No amount of other passing tests removes a release test gap — it is a hard stop under 21 CFR 211.165.
---

References

  1. Lieberman, H.A.; Rieger, M.M.; Banker, G.S. (eds.), Pharmaceutical Dosage Forms: Disperse Systems, Vols. 1–3, 2nd ed. Marcel Dekker, New York, 1996.
  2. Aulton, M.E.; Taylor, K.M.G. (eds.), Aulton's Pharmaceutics: The Design and Manufacture of Medicines, 5th ed. Elsevier, Edinburgh, 2018.
  3. Brummer, R., Rheology Essentials of Cosmetic and Food Emulsions, 1st ed. Springer, Berlin, 2006.
  4. Adejare, A. (ed.), Remington: The Science and Practice of Pharmacy, 23rd ed. Academic Press, London, 2021.
  5. Chang, R.-K.; Raw, A.; Lionberger, R.; Yu, L., 'Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products,' AAPS Journal, 2013, 15(1), 41–52. DOI: 10.1208/s12248-012-9411-0
  6. Chang, R.-K.; Raw, A.; Lionberger, R.; Yu, L., 'Generic development of topical dermatologic products, Part II: Quality by design for topical semisolid products,' AAPS Journal, 2013, 15(3), 674–685. DOI: 10.1208/s12248-013-9472-8
  7. Buhse, L.; Kolinski, R.; Westenberger, B.; et al., 'Topical drug classification,' International Journal of Pharmaceutics, 2005, 295(1–2), 101–112. DOI: 10.1016/j.ijpharm.2005.01.032
  8. Islam, M.T.; Rodríguez-Hornedo, N.; Ciotti, S.; Ackermann, C., 'Rheological characterization of topical carbomer gels neutralized to different pH,' Pharmaceutical Research, 2004, 21(7), 1192–1199. DOI: 10.1023/B:PHAM.0000033006.11619.07
  9. United States Pharmacopeia and National Formulary (USP-NF), General Chapter <3> Topical and Transdermal Drug Products—Product Quality Tests. United States Pharmacopeial Convention, Rockville, MD. [Confirm against current official USP-NF text.]
  10. United States Pharmacopeia and National Formulary (USP-NF), General Chapter <755> Minimum Fill. United States Pharmacopeial Convention, Rockville, MD. [Confirm against current official text.]
  11. United States Pharmacopeia and National Formulary (USP-NF), General Chapter <791> pH. United States Pharmacopeial Convention, Rockville, MD. [Confirm against current official text.]
  12. United States Pharmacopeia and National Formulary (USP-NF), General Chapter <905> Uniformity of Dosage Units. United States Pharmacopeial Convention, Rockville, MD. [Confirm against current official text.]
  13. United States Pharmacopeia and National Formulary (USP-NF), General Chapter <912> Viscosity—Rotational Methods (with cross-references to <911>, <913>, <1911>, <1912>). United States Pharmacopeial Convention, Rockville, MD. [Confirm against current official text.]
  14. United States Pharmacopeia and National Formulary (USP-NF), General Chapter <921> Water Determination. United States Pharmacopeial Convention, Rockville, MD. [Confirm against current official text.]
  15. United States Pharmacopeia and National Formulary (USP-NF), General Chapter <1112> Application of Water Activity Determination to Nonsterile Pharmaceutical Products. United States Pharmacopeial Convention, Rockville, MD. [Confirm against current official text.]
  16. United States Pharmacopeia and National Formulary (USP-NF), General Chapter <467> Residual Solvents. United States Pharmacopeial Convention, Rockville, MD. [Confirm against current official text.]
  17. United States Pharmacopeia and National Formulary (USP-NF), General Chapters <232> Elemental Impurities—Limits and <233> Elemental Impurities—Procedures. United States Pharmacopeial Convention, Rockville, MD. [Confirm against current official text.]
  18. United States Pharmacopeia and National Formulary (USP-NF), General Chapter <1151> Pharmaceutical Dosage Forms. United States Pharmacopeial Convention, Rockville, MD. [Confirm against current official text.]
  19. International Council for Harmonisation (ICH), Q3D(R2) Guideline for Elemental Impurities, including Appendix 5 (Cutaneous and Transcutaneous Route). ICH, Geneva, 2022. Available at: https://www.ich.org
  20. International Council for Harmonisation (ICH), Q3C(R8) Guideline for Residual Solvents (Class 1 benzene limit). ICH, Geneva, 2021. Available at: https://www.ich.org
  21. International Council for Harmonisation (ICH), Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances. ICH, Geneva, 1999. Available at: https://www.ich.org
  22. International Council for Harmonisation (ICH), Q1A(R2) Stability Testing of New Drug Substances and Products, §2.2.7.3 (Semi-permeable containers). ICH, Geneva, 2003. Available at: https://www.ich.org
  23. U.S. Food and Drug Administration, Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs (Guidance for Industry, final March 2026). FDA, Silver Spring, MD. Available at: https://www.fda.gov/drugs/guidance-documents-drugs
  24. U.S. Food and Drug Administration, Reformulating Drug Products That Contain Carbomers Manufactured With Benzene (Guidance for Industry, December 2023). FDA, Silver Spring, MD. Available at: https://www.fda.gov/drugs/guidance-documents-drugs
  25. U.S. Food and Drug Administration, Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol (Guidance for Industry, May 2023, Rev. 1). FDA, Silver Spring, MD. Available at: https://www.fda.gov/drugs/guidance-documents-drugs
  26. U.S. Food and Drug Administration, Guide to Inspections of Topical Drug Products. FDA, Rockville, MD, July 1994. Available at: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/inspection-guides
  27. U.S. Food and Drug Administration, Risk of Benzene Contamination in Certain Drugs (FDA Drug Safety Alert, March 2025 and ongoing). FDA, Silver Spring, MD. Available at: https://www.fda.gov/drugs/drug-safety-and-availability
  28. U.S. Code of Federal Regulations, Title 21, Part 211: Current Good Manufacturing Practice for Finished Pharmaceuticals. Sections 211.84(d) (Component testing), 211.110 (In-process controls), 211.160 (General requirements for laboratory controls), 211.165 (Testing and release for distribution). U.S. Government Publishing Office, Washington, DC. Available at: https://www.ecfr.gov